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ABSTRACT 
 
The spread of the tuberculosis (TB) has been further accelerated by the emergence of multi- 
and extensively-drug resistant Mycobacterium tuberculosis strains, thereby further increasing 
the need to characterise novel drug targets and develop anti-TB agents. The cell wall of M. 
tuberculosis plays a key role in survival of the pathogen in the host cell, making it an 
attractive drug target. The findings in this thesis present three different studies that contribute 
to the discovery of novel drug targets. Using a whole-cell screening approach and the 
generation of spontaneous drug-resistant mutants in M. smegmatis, a surrogate model of M. 
tuberculosis, we identified a new inhibitor which targets glycerol metabolism. The two 
remaining studies involved studying the biosynthetic pathways of critical cell-wall 
components. In this first study, Conditional expression specialised transduction essentiality 
test was used to confirm the essentiality of MSMEG3859 in M. smegmatis, an enzyme which 
generates mannose donors that are utilised in the biosynthesis of higher order Phosphatidyl-
myo-inositol mannosides, Lipomannan (LM) and Lipoarabinomannan (LAM), important 
immunomodulators in mycobacteria. Furthermore, a deletion mutant of Protein kinase H 
(PknH) in M. tuberculosis was used to demonstrate its importance in the production of 
LM/LAM and Phthiocerol dimycoserosates, a glycolipid that is also involved in TB 
pathogenesis. Thus, both Ppm1 and PknH can potentially be used as future therapeutic targets 
against M. tuberculosis. 
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1.1 Mycobacterium species 
Mycobacterium is a genus of Actinomycetales of which other genera include 
Corynebacterium, Norcardia, Rhodococcus and Streptomyces (Brennan and Nikaido, 
1995). Mycobacteria are aerobic, rod-shaped, non-motile and non-sporulating with 
high guanine and cytosine content in their genomes. Although they do not retain the 
crystal violet stain very well using the Gram method, they are still classified as Gram-
positive. All mycobacteria share a unique, thick, waxy, lipid-rich cell wall; however, 
their most defining feature is the presence of distinctive mycolic acids that contribute 
to the cell wall‟s hydrophobicity (Minnikin and Goodfellow, 1980; Dover et al., 2004). 
Mycobacteria can be stained using concentrated dyes, particularly when combined 
with heat, but are resistant to decolourisation by dilute acid or ethanol-based 
procedures. This physical property is referred to as acid-fastness and can be 
detected using the Ziehl-Neelsen staining method (Harada et al., 1976). 
 
The species within the Mycobacterium genus have variable growth rates, allowing 
them to be divided into fast-growing mycobacteria and slow-growing mycobacteria 
(Table 1.1). Highly pathogenic bacteria, including Mycobacterium tuberculosis, the 
causative agent of tuberculosis (TB) and Mycobacterium leprae, the causative agent 
of leprosy, are characterised by their slow generation times. In comparison to 
Escherichia coli, which divides every 20 min, M. tuberculosis divides extremely 
slowly, every 15 to 20 hours, and colonies are not visible on plates for 4 to 6 weeks. 
Mycobacterium smegmatis is a faster-growing species, which can grow visible 
colonies in 3 to 5 days. This particular species of Mycobacterium is non-pathogenic 
and commonly used as a model for studying M. tuberculosis. 
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The M. tuberculosis complex is a group of closely related Mycobacterium species 
which have up to 99% similarity at the DNA level (Brosch et al., 2002). Species 
include M. tuberculosis, Mycobacterium bovis, “Mycobacterium canettii” and 
Mycobacterium africanum.  
 
Table 1.1. List of slow-growing and fast-growing Mycobacterium species. 
Slow-growing mycobacteria Fast-growing mycobacteria 
M. tuberculosis complex 
 M. tuberculosis 
 M. bovis 
 M. africanum 
 M. canetti 
 M. microti 
 
M. chelonae clade 
 M. abscessus 
 M. chelonae 
 M. bolleti 
 
M. avium complex 
 M. avium 
 M. kansaii 
 M. ulcerans 
 
M. vaccae clade 
 M. faurum 
 M. vaccae 
 
M. kansasii clade 
 M. gastri 
 M. kansasii 
Ungrouped 
 M. phei 
 M. smegmatis 
 
1.2 History of tuberculosis 
Tuberculosis (TB) is a major cause of death worldwide and has been since ancient 
times. The aetiological agent of TB, M. tuberculosis is hypothesised to have 
originated approximately 150 million years ago (Hayman, 1984; Daniel, 2006). Due to 
the low mutation rate of M. tuberculosis, estimations into its time of origin have 
concluded that early predecessor strains existed 3 million years ago in East Africa 
where early hominids would have been infected (Gutierrez et al., 2005). Present 
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strains of M. tuberculosis, which are responsible for the majority of TB cases 
worldwide, are the result of an evolutionary bottleneck around 20,000 years ago 
(Kapur et al., 1994; Brosch et al., 2002; Gutierrez et al., 2005). All modern members 
of the M. tuberculosis complex, including M. africanum, “M. canetti” and M. bovis, are 
derived from a common ancestor (Daniel, 2006; Supply et al., 2013). The migrant 
human population from East Africa may have carried their diseases, including TB, to 
other parts of the world. Archaeological evidence of early TB has been identified 
using molecular and paleomicrobiological studies in Egyptian mummies dating from 
3000-2400 BC (Zink et al., 2001) and more recently in a 9000 year old mummy from 
a Neolithic settlement in the Eastern Mediterranean using PCR techniques and lipid 
biomarkers analysis (Hershkovitz et al., 2008).  
 
TB was first documented as the term phthisis (also known as consumption) by the 
ancient Greek physician Hippocrates in 460 BC who identified symptoms of chest 
pain and coughing, frequently with blood in the sputum amongst young adults with 
the disease (Coar, 1982; Daniel, 2006). Although Hippocrates recognised its 
prevalence and cause of fatality, at the time, it was thought of as a hereditary disease 
until Aristotle described it as being infectious. However, it was the renowned Greek 
physician Clarissimus Galen who first described phthisis as an ulceration of the 
lungs, accompanied by a cough, fever, and wasting away of the body (Pease, 1940). 
Over the following centuries, documentation of TB became sparse, that is until the 
17th Century, when TB epidemics across Europe became the main cause of death 
and were known as the “Great White Plague”. During this time, physician René 
Laennec, known for inventing the stethoscope, studied the pathogenesis of TB and 
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described the pathology of the infection as being either pulmonary or extrapulmonary 
(Daniel, 2004). However, the major turning point in TB research came in 1882 when 
Robert Koch discovered that the tubercle bacillus was the cause of the disease, work 
for which he was awarded a Nobel Prize in 1905 (Koch, 1932). This significant 
discovery proved to be key to developing new, effective therapies for treating TB. 
Koch attempted to develop a cure for TB by producing tuberculin, a glycerine extract 
of tubercle bacilli. Although tuberculin proved to be ineffective as a cure, it was later 
utilised by Clemens von Pirquet as a diagnostic agent for TB and eventually a 
purified protein derivative (PPD) was developed into the tuberculin skin test which is 
still used today (Daniel, 2006). 
 
Whilst the scientific community was advancing its knowledge of TB through the 
discovery of tubercle bacillus as its cause, this coincided with a decrease in the 
mortality rates of TB patients during the mid-19th Century despite the absence of 
antibiotics at that time (Wilson, 1990). Although the exact cause for this reduction is 
unknown, it could have been aided by the idea that a regimen of rest and good 
nutrition was effective in treating the disease. This idea was popularised by Herman 
Brehmer through the formation of institutions, such as the sanatoria created in 1859, 
where TB patients were able to recuperate in isolation, thereby preventing the 
transmission of the infection (Cox, 1923; Daniel, 2006). 
 
In an attempt to treat the diseased lungs of patients, pulmonary collapse therapy 
(artificial pneumothorax) and thoracoplasty procedures were employed to force 
compression of the lung cavities by inserting air through the pleural space (Singer, 
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1936). These invasive techniques, popular during the 20th Century, were used to 
allow the lung to heal from lesions; however, there are many risks and complications 
associated with these operations including tissue infection and empyema, which has 
discouraged the continued use of these treatments (Heaton, 1936). 
 
The development of the BCG (Bacille Camlette-Guérin) vaccine was the first 
successful immunisation approach to tackling TB. The idea of vaccines was 
pioneered by Edward Jenner who discovered that healthy individuals could be 
immunised against smallpox using the pus from the hand of a milkmaid infected with 
cowpox (Riedel, 2005). Albert Calmette and Camille Guérin, taking inspiration from 
Jenner‟s work, produced an attenuated strain of M. bovis, the causative agent of 
bovine TB, which proved to be an effective vaccine against TB particularly when 
given at an early age (Sakula, 1983; Daniel, 2005). Although there is much debate 
concerning how the efficacy of this vaccination strategy varies according to 
geographical location, BCG remains the only available vaccine against TB (Fine, 
1995).  
 
1.3 Immune response to tuberculosis 
M. tuberculosis are carried in droplet nuclei particles, which can remain in the 
atmosphere for several hours after exhalation by an active TB sufferer. Transmission 
occurs when these infectious droplets are inhaled into the respiratory tract, where the 
majority of the bacilli become trapped in the upper airways. If the bacteria reach the 
lungs, they are phagocytosed by alveolar macrophages. This phagocytosis process 
is mediated by the expression of several host receptors including complement 
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receptors (CR1 and CR2), C-type lectin receptors (CLRs) and scavenger receptors 
(SRs) (Philips and Ernst, 2012). Bacteria contained within the phagosomes can be 
killed by several mechanisms including fusing with lysosomes to form a 
phagolysosome, and through the production of reactive oxygen and nitrogen 
intermediates, resulting in necrosis or apoptosis (Russell, 2001). However, from this 
point, M. tuberculosis has the ability to avoid the normal sequence of events by 
inhibiting the maturation process of the phagosome, by limiting acidification to pH 6.4 
and blocking fusion with lysosomes (Houben et al., 2006; Deretic et al., 2006). This 
evasion process can be overcome when antigen-specific T-lymphocytes are recruited 
to the macrophage and further stimulate it to inhibit the growth of, or kill, 
mycobacteria, a response modulated by the secretion of interferon-γ (IFN-γ) 
(Schluger and Rom, 1998).  
 
In the majority of cases, M. tuberculosis infection follows a cascade of events which 
enables the pathogen to survive in a dormant state within host cells through 
granuloma formation, a characteristic feature of TB (Figure 1.1). Bacterial uptake by 
alveolar macrophages induces a robust proinflammatory response, which drives the 
recruitment of mononuclear cells from blood vessels (Russell, 2007). Lymphocytes 
migrate to the site of infection and begin the formation of the granuloma which 
comprises a core of infected macrophages, surrounded by foamy macrophages and 
an external layer of lymphocytes further stratified by extracellular components 
(Russell, 2007). This host response forms the „containment‟ phase of the infection as 
the granuloma is usually sufficient to limit replication and keep the primary infection 
enclosed, preventing it from advancing to the active state. However, a subsequent 
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defect in cell-mediated immunity, for example by co-infection with HIV, malnutrition or 
old age (Russell, 2007), can lead to the failure of this containment of the infection. In 
this event, the granuloma can rupture to allow the release of infectious bacilli into the 
airways, causing reactivation of the disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic representation of granuloma formation in humans. (Russell, 
2007). 
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1.4 Epidemiology of tuberculosis 
The steady decline of TB mortality, which began in the mid-19th Century, continued 
into the 20th Century due to improved healthcare provisions, BCG vaccination 
programmes and the development of antibiotic therapies, giving hope that the 
disease might be eradicated (Lienhardt et al., 2012). However, a resurgence of the 
disease during the 1990s was aggravated by several factors, including the 
emergence of the HIV/AIDS pandemic and drug-resistant M. tuberculosis strains, and 
forced the World Health Organisation (WHO) to declare TB a global health 
emergency.  
 
WHO estimates that a third of the world‟s population is currently latently infected with 
M. tuberculosis. In 2011, there were 8.7 million new cases of TB and 1.4 million 
deaths from TB (WHO, 2012). Heavily populated countries of Asia, including India, 
China, Indonesia, Bangladesh and Pakistan, together contribute to half of all new 
cases (Dye, 2006); however, the highest incidence of TB cases is in the Sub-
Saharan region of Africa, which has been particularly impacted by the HIV/AIDs 
pandemic (Figures 1.2 & 1.3) (Nunn et al., 2005). HIV infection has rapidly become a 
significant risk factor for TB as the suppression of the immune system can increase 
the annual risk of reactivating latent M. tuberculosis by 5-15% (Nunn et al., 2005). In 
Eastern European countries, particularly those of the former Soviet Union, a rise in 
the incidence of TB cases has been associated with socio-economic changes and a 
decline of an appropriate healthcare system, leading to problems involving drug 
resistance (Frieden et al., 2003). Overall, the recent increase in global TB cases is 
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largely a consequence of HIV infection and the emergence of multi-drug resistant 
(MDR-TB) strains. 
Figure 1.2. Map showing estimated TB incidence rates in the year 2011. (WHO, 2012). 
 
 
 
 
 
Figure 1.3. Map showing estimated HIV prevalence in TB cases in the year 2011. 
(WHO, 2012) 
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1.5 Treatment 
1.5.1 Anti-tuberculosis drugs 
The discovery of streptomycin, isolated from Streptomyces griseus in the 1940s by 
Albert Schatz and Selman Waksman, as the first effective antibiotic against M. 
tuberculosis, initiated the beginning of anti-tuberculosis chemotherapy (Schatz et al., 
2005). Streptomycin became the first drug available for the treatment of TB until 
evidence of acquired resistance reduced its efficacy against inhibition of the tubercle 
bacillus, possibly due to administration as a single drug therapy (Wolinsky et al., 
1948). Post this discovery, it became evident that the use of multiple drugs in the 
treatment of TB was necessary to limit the generation of drug-resistant strains. In 
1946, Jorgen Lehmann found that para-aminosalicylic acid (PAS) stimulates oxygen 
depletion in the tubercle bacillus (Bernheim, 1940) and PAS became another 
effective drug against TB (Lehmann, 1946). 
 
A major breakthrough in TB chemotherapy came in 1952 with the introduction of 
isoniazid (INH), a highly active drug with no substantial side effects, which displayed 
a high specificity for the tubercle bacillus (Y Zhang, 2003). The 1950s and 1960s are 
considered to be the golden era of anti-TB drug discovery as many prominent 
antibiotics were developed during this time including pyrazinamide (PZA) (Malone et 
al., 1952), ethionamide (ETH) (Liebermann et al., 1956), ethambutol (EMB) (J P 
Thomas et al., 1961), cycloserine (Kurosawa, 1952) and rifampicin (RIF) (Maggi et 
al., 1966). 
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The current drug regimen administered to TB patients consists of a six-month therapy 
divided into two phases: an initial intensive phase for the first two months followed by 
a continuation phase for the remaining four months (WHO, 2012). The initial two-
month intensive phase aims to kill actively growing and semi-dormant bacilli through 
the employment of the first-line anti-TB drugs INH, EMB, PZA and RIF (Table 1.2). 
These drugs can be further allocated into two groups: bactericidal drugs, which 
include INH and RIF, and bacteriostatic, which include EMB and PAS. In the first two 
weeks of treatment, INH is responsible for killing the large numbers of actively 
replicating bacilli. RIF and PZA kill the less active bacilli in the following weeks and 
rifampicin largely eliminates the remaining dormant bacilli in the continuation phase. 
Although the initial two-month therapy is sufficient to eliminate the tubercle bacilli, the 
follow-up continuation phase is vital to eliminate any remaining bacilli and is 
necessary to diminish the risk of failure of the treatment programme or relapse of the 
infection. In this second phase, INH and RIF are taken for a further four months 
(Maartens and Wilkinson, 2007). 
 
 
 
 
 
 
 
Chapter 1  General Introduction 
13 
 
Table 1.2. Drugs used in the current drug regimen. 
 
Drug  
 
 
MIC 
(µg/µl) 
 
Mechanism of 
action 
 
Important 
genes 
 
isoniazid (INH) 
 
 
 
 
 
 
 
 
 
 
0.01 – 
0.2 
 
 
 
Inhibition of mycolic 
acid synthesis 
 
 
 
 
katG 
 
inhA 
pyrazinamide (PZA) 
 
 
 
 
 
 
20-100 
 
 
Acidification of 
cytoplasm & 
decrease membrane 
potential 
 
 
 
 
 
pncA 
ethambutol (EMB) 
 
 
 
 
 
 
1-5 
 
 
Inhibition of 
arabinogalactan & 
lipoarabinomannan 
synthesis 
 
 
 
 
embCAB 
rifampicin (RIF) 
 
 
 
 
 
0.05-
2.5 
 
 
 
 
Inhibition of RNA 
synthesis 
 
 
 
 
 
rpoB 
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INH is a prodrug and is activated by a catalase-peroxidase enzyme (KatG), which is 
present in M. tuberculosis (Figure 1.4) (Zhang et al., 1992). The primary mode of 
action of INH is to inhibit the synthesis of mycolic acids, which are vital components 
of the mycobacterial cell wall, by targeting the enoyl-ACP reductase (InhA) (Winder 
and Collins, 1970; Banerjee et al., 1994). The specific mechanism of action involves 
coupling the isonicotinic acyl radical with NAD to form a complex which binds tightly 
to InhA, preventing the formation of mycolic acids (Rozwarski et al., 1998).  
 
Figure 1.4. Activation of the prodrug isoniazid (INH) to form isonicotinic acyl-NADH 
(Rozwarski et al., 1998). 
 
PZA is also a prodrug and is converted into its active form, pyrazinoic acid, by a 
nicotinamidase encoded by pncA (Figure 1.5) (Zhang et al., 2003).  Pyrazinoic acid 
leads to acidification of the cytoplasm and decreasing membrane potential, which is 
required for membrane transport (Ying Zhang, Wade, et al., 2003). EMB has been 
found to target the embCAB genes, which encode the arabinosyltransferase 
responsible for arabinan synthesis (Belanger et al., 1996; Telenti et al., 1997); 
therefore EMB inhibits the biosynthesis of arabinogalactan (AG) and 
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lipoarabinomannan (LAM) (Mikusová et al., 1995).  RIF targets nucleic acid synthesis 
by binding to the β-subunit of the DNA-dependent RNA polymerase encoded by rpoB 
(Blanchard, 1996). 
 
Figure 1.5. Conversion of pyrazinamide (PZA) to pyrazinoic acid (Zhang et al., 2003). 
 
1.5.2 Directly Observed Treatment – Short Course 
Despite the best efforts to control TB, the multidrug regimen has not been successful 
in eradicating TB due to the emergence of drug resistance. A major reason for this is 
that not all patients complete the full treatment as its duration is deemed too long and 
burdensome to comply with (Zhang, 2005). WHO has recommended the use of the 
Directly Observed Treatment Short course (DOTS) as an effective method of 
controlling the transmission of TB and ensuring that patients adhere to the full 
treatment (WHO, 2012).  DOTS therapy is composed of five points: political 
commitment, use of sputum smear microscopy in case detection, directly observed 
treatment for at least the first two months, efficient drug supply and monitoring of 
results (Maartens and Wilkinson, 2007; WHO, 2012). DOTS therapy involves a 
trained observer being present to monitor patients while taking each dose of 
medication. This system has successfully been used to obtain high rates of treatment 
completion, reduce the development of acquired drug resistance and prevent relapse 
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of infection (Frieden et al., 2003). The DOTS-plus variant, which includes drug-
susceptibility testing and availability of second-line drugs, was introduced in 1998 in 
an attempt to treat drug-resistant TB cases (Mukherjee et al., 2004). In addition to 
this, WHO has established a new six-point Stop TB Strategy, which aims to build on 
the success of DOTS and raise awareness of the rising incidence of drug-resistant 
TB strains (Raviglione and Uplekar, 2006; WHO, 2012). 
 
1.5.3 Drug resistance 
Multidrug-resistant TB (MDR-TB) is caused by those TB strains that are resistant to 
both INH and RIF, which are two of the first-line drugs in TB treatment. Extensively 
drug-resistant TB (XDR-TB) is caused by those strains that are resistant to both INH 
and RIF, in addition to fluoroquinolones and at least one injectable second-line drug 
such as capreomycin, amikacin and kanamycin (Maartens and Wilkinson, 2007). TB 
drug resistance continues to increase: the estimated number of cases worldwide was 
expected to be 630,000 for MDR-TB and 40,000 for XDR-TB in 2011 (WHO, 2012).  
 
Drug resistance can emerge by three interconnected mechanisms: i) acquired 
resistance, which involves the conversion of wild-type strains to drug-resistant 
strains; ii) amplified resistance, which occurs due to inappropriate chemotherapy; and 
iii) transmitted resistance, which involves the transmission of drug-resistant cases 
(Jassal and Bishai, 2009; Da Silva et al., 2011). Although acquired and amplified 
resistance are the principal mechanisms by which drug resistance is produced, 
transmission resistance accounts largely for the recent rise in XDR-TB cases (Jassal 
and Bishai, 2009).  
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At present, it is very difficult to treat cases of MDR-TB and XDR-TB as the bacilli are 
resistant to the drugs commonly used in the standard regimen. Patients with drug-
resistant TB are therefore currently treated with at least three drugs that the organism 
is fully susceptible to and which need to be taken for typically a minimum duration of 
18 to 24 months (Frieden et al., 2003; Jassal and Bishai, 2009).  However, these 
reserve drugs are less efficient in eliminating the infection, more toxic than standard 
drugs and need to be taken daily or even several times a day (Frieden et al., 2003). 
As a result, greater morbidity and mortality is associated with XDR-TB compared to 
TB cases with no drug resistance (Jassal and Bishai, 2009).  
 
1.6 Mycobacterial cell wall 
The cell wall of M. tuberculosis consists of a lipid-rich, hydrophobic barrier, which is 
responsible for its acid-fastness and hydrophobic properties (Kaur et al., 2007). The 
complexity of the cell wall also makes it difficult for antibiotics to enter the bacterium 
(Minnikin et al., 2002). The cell-wall structure is comprised of a mycolyl-
arabinogalactan-peptidoglycan (mAGP) complex, consisting of a peptidoglycan (PG) 
layer that is covalently attached to arabinogalactan (AG), which is further esterified to 
complex lipids known as mycolic acids. Non-covalently linked biosynthetically related 
glycolipids and lipoglycans, including phosphatidyl-myo-inositol mannosides (PIMs), 
lipomannan (LM) and lipoarabinomannan (LAM) are also embedded in the cell wall 
(Figure 1.6) (Brennan, 2003). Mycolic acids are α-alkyl β-hydroxylated fatty acids 
composed of 60 to 90 carbon residues and form part of the hydrophobic external 
layer of the cell wall (Chatterjee et al., 1993). The outer membrane segment is further 
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decorated with solvent-extractable lipids, including dimycolyltrehalose (TDM), 
phthiocerol dimycocerosates (PDIM), phenolic glycolipids (PGL) and sulfolipids (SL). 
 
 
Figure 1.6. Representation of the M. tuberculosis cell wall. The cell-wall structure 
consists of a peptidoglycan layer covalently attached to arabinogalactan, which is further 
esterified to mycolic acids. Non-covalently linked biosynthetically related glycolipids, 
including PIMs, LM and LAM are embedded in the cell wall. The outer membrane is further 
decorated with solvent-extractable lipids. AG, Arabinogalactan; DAT, Diacyl trehalose; LAM, 
Lipoarabinomannan; mAG, mycolyl arabinogalactan; PAT, Penta-acyl Trehalose; PDIM, 
Phthiocerol dimycocerosate; PG, Peptidoglycan; PIM6, Phosphatidylinositol hexamannoside. 
Adapted from Minnikin et al., 2002. 
 
1.6.1 Peptidoglycan (PG) 
The PG layer forms the backbone of the mAGP complex, forming a rigid layer 
external to the plasma membrane to provide cellular shape and resistance to osmotic 
pressure. Categorised as A1γ in accordance with the Schleifer and Kandler 
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classification system (Schleifer and Kandler, 1972), the structure of mycobacterial PG 
shares similarity with other Gram-negative bacteria, including E. coli and Bacillus 
species (Figure 1.7). However, the PG M. tuberculosis and M. smegmatis is distinct 
from that found in other species as it is composed of linear chains of repeating 
(14)-N-acetylglucosamine (GlcNAc) and N-glycolyl muramic acid (Mur) residues, 
where the N-acetyl group is oxidised to N-glycolyl (Azuma et al., 1970; Mahapatra et 
al., 2005). Tetrapeptide side chains consisting of L/D-alanine, D-isoglutamine and 
meso-diaminopimelic acid (mDAP) components are attached to Mur components, 
which are cross-linked to AG (Wietzerbin et al., 1974; Lederer et al., 1975). The 
peptide chains are more heavily cross-linked in mycobacteria at 70-80% than in other 
species, such as E. coli, where cross-linking between peptides is around 50% 
(Vollmer and Höltje, 2004). This increased cross-linking adds to the structural 
integrity of the bacterium. While two-thirds of the cross-links are formed between the 
carboxyl group of a terminal D-alanine and the amino group of DAP, commonly found 
in most bacterial species, one-third of the peptide links occurs between two DAP 
residues in mycobacterial PG (Wietzerbin et al., 1974). In addition, PG is connected 
to the galactan domain of AG via a „linker unit‟, whereby the carbon-6 position of Mur 
residues forms a phosphodiester bond with the carbon-1 position of GlcNAc, which is 
(1→3) linked to an α-L-rhamnose (Rha) residue (McNeil et al., 1991). Although the 
synthesis of M. tuberculosis PG is poorly understood, the process is considered to be 
similar to the E. coli PG biosynthetic pathway (van Heijenoort, 2001). 
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Figure 1.7. Structure of M. tuberculosis peptidoglycan. Broken lines designate cross-
links to arabinogalactan or to the sugar and peptide stems of neighbouring monomeric units. 
R1, H or the linker unit of AG; R2, OH, NH2 or glycine; R
3, OH or NH2; R
4, OH or amidated 
cross-link to m-DAP. Ala, Alanine; Glu, Glutamate; GlcNAc, N-acetylglucosamine; mDAP, 
meso-diaminopimelic acid; MurNGlyc, N-glycolyl muramic acid. 
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1.6.2 Arabinogalactan (AG) 
AG forms a major part of the M. tuberculosis cell wall, accounting for approximately 
35% of the overall mycobacterial mass. This unique polysaccharide is predominantly 
composed of arabinose (Ara) and galactose (Gal) residues, which are both present in 
their furanose ring form as arabinofuranose (Araf) and galactofuranose (Galf) (Figure 
1.8) (McNeil et al., 1987).  
Figure 1.8. Structure of arabinogalactan in M. tuberculosis. The galactan component, 
composed of 30 Galf residues, is attached to the peptidoglycan via a phosphodiester linker 
unit. Three arabinan chains are connected to the galactan strand via attachment to positions 
8, 10 and 12 (Alderwick et al., 2006). The branched arabinan structure is covalently attached 
to mycolic acids through a distinct hexa-arabinofuranosyl (Ara6) motif. A succinyl (Bhamidi et 
al., 2008) or galactosamine (Lee et al., 2006) residue is attached to the 3,5-α-D-Araf units. 
Araf, Arabinofuranose; Galf, Galactofuranose; GlcNAc, (14)-N-acetylglucosamine; Myc, 
Mycolic acid; Mur, Muramic acid; Rha, α-L-rhamnose. Adapted from Jankute et al., (2012). 
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As described previously, PG is covalently attached through a phosphodiester linker 
unit to the galactan component reducing end of AG, whereas mycolic acids are linked 
to the non-reducing end of AG which is composed of the Ara residues (Nikaido et al., 
1993). The lack of repeating units of sugar residues makes the structure of 
mycobacterial AG dissimilar to other bacterial species; however, its structure consists 
of several distinct structural motifs (Daffé et al., 1990). The galactan region of AG is 
composed of a linear chain of 30 units of alternating 5- and 6-linked β-D-Galf 
residues. The highly branched arabinan chains, each containing approximately 30 
Araf residues, are attached to the carbon-5 position of some 6-linked Galf residues 
(Daffé et al., 1990); three arabinan chains can be linked to one galactan strand via 
attachment to the 8th, 10th and 12th galactosyl residues (Alderwick et al., 2006). 
These arabinan chains are mostly comprised of 5-linked α-D-Araf residues where 
branching is introduced at the carbon-3 hydroxyl position to form 3,5-α-D-Araf 
residues (Daffé et al., 1990). The arabinan structure at the non-reducing termini of 
AG consists of a characteristic hexa-arabinofuranosyl (Ara6) motif [β-D-Araf-(1→2)-α-
D-Araf]2-3,5-α-D-Araf-(1→5)-α-D-Araf, where mycolic acids are located in clusters of 
four attached to the position 5 of the β-D-Araf unit and the penultimate 2-α-D-Araf 
residue (McNeil et al., 1991); however only two-thirds of these motifs are mycolated 
(McNeil et al., 1991). The attachment of a succinyl ester (Bhamidi et al., 2008) or 
galactosamine residue (Lee et al., 2006) to the inner 3,5-α-D-Araf units completes the 
AG structure. 
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1.6.3 Mycolic acids  
Mycolic acids are a major component of mycobacteria, accounting for approximately 
60% of the dry mass of the bacterium. They are predominantly esterified to AG and 
present as solvent-extractable free lipids such as trehalose monomycolates (TMM), 
trehalose dimycolates (TDM) and glucose monomycolates (GMM) (Minnikin et al., 
2002). In mycobacteria, mycolic acids are composed of 70-90 carbon residues and 
as such, are the largest amongst the bacteria (Goodfellow and Minnikin, 1981). 
Mycolic acids are very hydrophobic α-alkyl branched, β-hydroxylated fatty acids. 
They consist of a meromycolate moiety with carbon chain lengths of up to C56, and 
long saturated α-branch ranges from C20 to C24 in length and possess at least two 
stereogenic centres at the positions α and β to the carboxylic acid (Brennan and 
Nikaido, 1995). Although the generic mycolate structure is well conserved, various 
classes of mycolic acids can be defined by the presence of modifications at two mid-
chain positions with functional groups in M. tuberculosis including cis and trans 
cyclopropane rings, cis and trans double bonds and keto-, methoxy-, epoxy- and 
wax-ester functionality (Barry et al., 1998).  The key mycolic acid structures found in 
M. tuberculosis are classified into three groups: α-mycolates, keto-mycolates and 
methoxy-mycolates (Figure 1.9) (Minnikin et al., 1982; Minnikin et al., 2002; 
Watanabe et al., 2002). The most abundant type of mycolic acid containing no 
oxygen functional groups at the proximal or distal positions of the meromycolate 
chain and two cis cyclopropane rings are known as α-mycolates (Minnikin et al., 
1982; Minnikin et al., 2002; Watanabe et al., 2002). Keto-mycolates and methoxy-
mycolates are oxygenated species comprising of one cis cyclopropane ring or one 
trans cyclopropane ring with and adjacent methyl branch, respectively.  
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Mycolic acid biosynthesis is vital for the survival and pathogenesis of M. tuberculosis. 
The presence of mycolic acids in the cell wall of M. tuberculosis gives rise to 
important characteristics including increased resistance to chemical damage and 
dehydration, low permeability to hydrophobic antibiotics all of which allow persistence 
of the bacterium within the host. Specific modifications of the mycolic acid structures 
are possibly linked to these unique characteristics. For example, the incorporation of 
cyclopropane residues in the chain contributes to the structural integrity of the cell 
wall structure (George et al., 1995) and is also reportedly essential for cord formation 
in mycobacteria (Glickman et al., 2001). In addition, a cis-cyclopropane modification 
allows the bacterium to grow readily inside macrophages, effectively hiding it from 
the host's immune system (Rao et al., 2005) whereas the trans-cyclopropane 
modification causes suppressive effects on M. tuberculosis-induced inflammation and 
virulence (Rao et al., 2006). 
 
Figure 1.9. Structure of mycolic acids found in M. tuberculosis.  
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1.6.4 Solvent-extractable free lipids 
As previously mentioned, the outer part of the membrane is intercalated with various 
solvent-extractable „free‟ lipids such as cord factor or TDM, PDIM, PGL and SL. 
These complex lipids are attached to the mAGP complex through hydrophobic 
interactions and some are specific to mycobacteria. 
 
1.6.5 Trehalose dimycolate (TDM) and trehalose monomycolate (TMM) 
Of the many glycosylated forms of mycolic acids, present in the outer layer of the 
mycobacterial cell envelope, the most widely studied is trehalose-6,6‟ dimycolate 
(TDM), also known as „cord factor‟ due to the characteristic cord-like structure of M. 
tuberculosis strains (Figure 1.10). Virulent M. tuberculosis strains subjected to 
petroleum ether extractions, which removes these lipids, have been shown to remain 
viable; however, they displayed a loss of virulence and were unable to form cord-like 
structures (Bloch, 1950). Non-virulent bacilli adsorbed with TDMs were able to inhibit 
leukocyte migration, which is only observed in virulent bacilli (Noll et al., 1956) and 
administration in small doses was toxic to laboratory animals (Bloch, 1950). TDM 
molecules comprise a trehalose sugar acylated with two mycolic acid residues. 
Trehalose monomycolate (TMM) possesses a single mycolate residue and is 
transported across the cell membrane for TDM biosynthesis or to form part of the 
mycolic acids that are esterifed to the AG complex (Belisle, 1997). TDM is the most 
abundant of the non-covalently bound, surface-exposed lipids and is a virulence 
factor in mycobacteria. It is involved in many important immunological interactions 
such as the recruitment of cells for granuloma formation (Hunter et al., 2006) and in 
modulating the expression and production of cytokines (Lima et al., 2001). 
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Macrophages have been represented as a major target of the immune-stimulating 
effects of TDM; they possibly aid the entry of bacilli to inactivate macrophages 
(Porcelli and Besra, 2002). Besides, TDM shows diverse immunological activities 
including adjuvant and anti-tumour properties (Silva et al., 1985). 
Figure 1.10. Structure of and trehalose monomycolate (TMM) and trehalose dimycolate 
(TDM). 
 
1.6.6 Sulfolipids (SL) 
Sulfolipids (SLs) are a class of glycolipids found in virulent M. tuberculosis strains. 
They are composed of a trehalose 2-sulfate core, which is acylated with four fatty 
acyl substituents (Figure 1.11) (Goren et al., 1976). Studies have identified a clear 
correlation between the presence of SLs and virulence of TB in guinea pigs, which 
has led to the proposal that SLs play a prominent role in pathogenesis (Goren et al., 
1976). More recently, it has been shown that SLs block the release of tumour 
necrosis factor-α (TNF-α), induced by TDMs in macrophages, resulting in inhibition of 
granuloma formation in mice (Okamoto et al., 2006). Although mutant strains of M. 
tuberculosis devoid of SL did not significantly affect the replication, persistence and 
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pathogenicity of bacilli in guinea pig and cultured macrophages (Rousseau et al., 
2003), strains with disruption in the sulfolipid transporter MmpL8 were highly 
attenuated for the growth in the mouse model of TB (Converse et al., 2003).  
 
 
 
 
 
 
 
 
 
Figure 1.11. Structure of sulfolipid – SL-1. 
 
1.6.7 Phthiocerol dimycocerosate (PDIM) and phenolic glycolipid (PGL)  
Phthiocerol dimycocerosates (PDIMs) are highly non-polar waxes (Figure 1.12) found 
in the M. tuberculosis cell wall. They are composed of two myococerosic acids (long-
chain polymethyl-branched fatty acids) which are linked to a lipid core backbone of 
C34 and C34 long-chain β-diols known as phthiocerols (Minnikin et al., 2002). PDIM 
deficiency has been shown to be responsible for attenuation of virulent strains of M. 
tuberculosis in mice lungs which identified genes involved in the PDIM biosynthesis 
as being involved in TB pathogenesis (Cox et al., 1999; Camacho et al., 2001). 
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Further studies have shown that PDIMs participate in the early stages of M. 
tuberculosis infection by protecting the bacilli against reactive nitrogen intermediates 
and modulating the early immune response to infection (Rousseau et al., 2004). 
PDIMs have been demonstrated to control the invasion of macrophages by M. 
tuberculosis by modifying the organisation of lipids, thereby providing a protective 
niche for bacilli by preventing phagosome acidification (Astarie-Dequeker et al., 
2009). 
Figure 1.12. Structure of phthiocerol dimycocerosate (PDIM) and phenolic glycolipid 
(PGL) from “M. canetti”. PDIMs and PGLs have long chain β-diol backbones known as 
phthiocerols that are esterified with polymethyl-branched fatty acids known as 
mycocerosates.  
 
 
Phenolic glycolipids (PGLs) are structurally similar to PDIMs; however, they possess 
a glycosylated phenolic moiety at the end of the phthiocerol chain (Figure 1.12) 
(Daffé et al., 1987). These lipids are only found in slow-growing pathogenic bacteria 
such as M. kansasii, M. gastri, M. ulcerans, M. leprae, M. marinum, M. bovis, M. 
Chapter 1  General Introduction 
29 
 
tuberculosis (strain Canetti) (Daffé et al., 1987; Daffé and Lanélaelle, 1988). Studies 
have identified PGL as being involved in immunomodulatory responses such as 
inhibiting the release of proinflammatory chemokines and cytokines in Beijing 
lineages of M. tuberculosis (Reed et al., 2004). 
 
1.6.8 Lipoarabinomannan (LAM) and related biosynthetic precursors (LM and 
PIMs) 
Lipoglycans including LAM, its truncated form LM, and their biosynthetic precursor 
PIMs are another dominant feature of the M. tuberculosis cell wall and are embedded 
within the mAGP structure. The fully mature mycobacterial LAM comprises three 
distinct regions: a lipidated reducing end known as the phosphatidyl-myo-inositol (PI) 
anchor, the mannan core and the arabinan domain, which is capped with species-
specific motifs (Figure 1.13) (Hunter and Brennan, 1990; Chatterjee et al., 1992). The 
PI anchor, based on an sn-glycero-3-phosphate (1-D-myo-inositol), covalently 
attaches the lipoglycan to the cell wall (Hunter and Brennan, 1990). The current 
model of lipoglycan biosynthesis involves a series of steps where the PI anchor is 
further glycosylated as shown in the simplified linear pathway: from 
PI→PIM2→LM→LAM (Mishra et al., 2011).  
 
PIMs are synthesised by the addition of mannopyranose (Manp) units to the myo-
inositol ring of the PI precursor (Ballou and Lee, 1964). The smallest PIM residue is 
PIM2 in which PI is substituted with Manp residues at the 2 and 6 positions of the 
inositol moiety (Lee and Ballou, 1964). The PI unit can be elongated with up to five 
Manp residues to give rise to PIM6 (Briken et al., 2004). Two forms of acylated PIMs 
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are present in mycobacteria: Ac1PIMγ with the acyl group at the 3-OH of the myo-
inositol ring or 6-OH of the Manp residue and Ac2PIMγ, which is acylated at both, the 
3-OH of the myo-inositol ring and 6-OH of the Manp residue (Figure 1.13) (Khoo et 
al., 1995). Higher order PIMs, as well as LM are derived from Ac1PIM2, which is 
further glycosylated with a branched arabinan domain leading to the formation of 
LAM. The mannan core consists of approximately 30 Manp residues which form a 
linear α(1→6)-Manp backbone with α(1→2)-Manp side-chains. This linear 
polymannoside is linked to the branched D-arabinan domain comprising 
approximately 70 arabinofuranose (Araf) residues (Dinadayala et al., 2006; Birch et 
al., 2010; Mishra et al., 2011). The capping moieties of the arabinan domain vary 
between species; slow-growers such as M. tuberculosis display various degrees of 
short α(1→2) Manp chains (ManLAM) (Chatterjee et al., 1993), whereas caps of 
inositol phosphate are present in fast-growers such as M. smegmatis (PILAM) (Khoo 
et al., 1995) and non-capped LAM in M. chelonae (Guerardel et al., 2002). PIMs, LM 
and LAM are not only essential for mycobacterial growth and survival but they also 
exhibit a broad spectrum of immunomodulatory activities.  For example, ManLAM can 
inhibit IFN-γ-mediated activation of macrophages and the production of the Th1 
proinflammatory cytokines IL-12 and TNF-α (Mishra et al., 2011), as well as induce 
apoptosis in macrophages (Nigou et al., 2001). PILAM, in contrast, can induce a 
proinflammatory response in both macrophages and dendritic cells in a Toll-like 
receptor-2 (TLR-2) dependent manner (Vignal et al., 2003). Both PIMs and LAM 
enable mycobacteria to persist in phagosomes by preventing phagosome maturation 
(Vergne et al., 2003; Welin et al., 2008). 
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Figure 1.13. Structures of phosphatidyl-myo-inositol mannosides (PIMs), lipomannan 
(LM) and lipoarabinomannan (LAM). PI is glycosylated with Manp residues at the 2 and 6 
positions of the inositol moiety and acylated at position 3-OH of the myo-inositol ring or 6-OH 
of the Manp residue to generate Ac1PIM2 or acylated at both positions to generate Ac2PIM2. 
Ac1/Ac2PIM2 is further glycosylated with two α(1→6)-Manp residues and two α(1→6)-Manp 
residues to produce Ac1/Ac2PIM6. LM and LAM share a common mannan core composed of 
approximately 30 Manp residues which form a linear α(1→6)-Manp backbone with α(1→2)-
Manp side chains. A branched D-arabinan domain comprising approximately 70 Araf 
residues is attached to the mannan core to generate LAM. In M. tuberculosis, the non-
reducing termini arabinan is capped with mannan residues; however, capping moieties differ 
according to species. Here R1, R2, R3 and R4 represent potential acylation sites within the 
MPI anchor. The letters m, n, o and p depict different amount of glycosylations in LAM 
according to species. Araf, Arabinofuranose; Ino, Inositol; Manp, mannopyranose; MPI, 
Mannosyl phosphate inositol. 
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1.7 Mycobacterium smegmatis as a surrogate system in tuberculosis 
research 
The major hurdles involved with carrying out research with M. tuberculosis are its 
highly infectious nature, which poses risks for researchers and makes it necessary to 
work in a high containment Bio-Safety Level-3 (BSL-3) environment. Moreover, due 
to the long generation time of approximately 24 hours, experiments with M. 
tuberculosis take significantly longer compared to those involving fast-growing 
organisms. M. smegmatis overcomes these two major problems and is therefore 
extensively used in M. tuberculosis research; it is non-pathogenic and has an 
average generation time of 4 to 5 hours.  
 
M. smegmatis shares the same cell-wall structure of M. tuberculosis although it does 
generate some lipids that are different. However, the major cell wall components 
including PG, AG and mycolic acids are fairly well conserved between both species. 
Genome analysis shows that M. smegmatis, which has a genome the size of 7.0 Mb, 
shares more than 2000 homologues with M. tuberculosis. M. smegmatis is more 
tolerant than M. tuberculosis to alterations in cell-wall biosynthesis and some genes 
essential in M. tuberculosis are non-essential in M. smegmatis, making it an attractive 
model for TB research.  
 
1.8 Aims and objectives 
The recent emergence of MDR- and XDR-TB cases has worsened the global 
problem of TB, increasing the need to discover novel drug targets in M. tuberculosis. 
The main objective of this thesis was to identify and characterise novel drug targets 
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against TB focusing specifically on the mycobacterial cell wall. In addition, we wanted 
to biochemically characterise selected mutants which had disruptions in the 
biosynthesis of glycolipids. The aims are as follows: 
 
 To generate spontaneous mutants against chemical compounds from selected 
ChemBridge compounds and identify their drug targets. 
 To test the essentiality of a polyprenol monophosphomannose (PPM) 
synthase in lipoglycan biosynthesis of mycobacteria. 
 To biochemically characterise the pknH deletion mutant and analyse the 
composition of LM and LAM. 
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2 Identification of an inhibitor 
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2.1 Introduction 
2.1.1 TB drug discovery 
While there has been limited success in the development of new anti-TB drugs in the 
past 40 years, the emergence of drug resistance has reduced the efficacy of current 
front-line anti-TB agents. As a result, there is an urgent requirement for more 
effective compounds that are active against MDR and XDR-TB strains, and which act 
on novel drug targets and have no cross-resistance to existing drugs. Furthermore, to 
achieve global control of this epidemic, the next generation of TB drugs needs to 
overcome the limitations of current therapies. This includes drugs that can shorten 
the duration of treatment, lower the dosage frequency, be administered alongside 
HIV medications and reduce adverse side-effects.  
 
There is no clear consensus on the best method for TB drug discovery. Techniques 
range from the target-based approach, which relies on knowledge of essentiality and 
function of the protein to be screened against, to the whole cell-based approach, 
which involves screening against the whole bacterium. The availability of the M. 
tuberculosis genome sequence and the recent development of High-Throughput 
Screening (HTS) technologies have increased the potential to allow rational 
discovery and optimisation of new lead compounds, making target-based screening a 
particularly attractive strategy; however, to date, this approach has been largely 
unsuccessful in yielding novel drug targets. Reasons for the failure of this approach 
to identify new inhibitors include a lack of target validation, difficulty in predicting the 
biological effect of target inhibition on the whole bacterium and that essentiality of a 
target is not sufficient to ensure „druggability‟, where the target can bind with high 
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affinity to the drug. The whole cell-based screening approach using HTS of 
compound libraries has been more successful. The major advantages of this strategy 
include the ability to identify inhibitors with complex and pleiotropic modes of action 
causing cellular death and the ability to recognise potential holistic interactions of a 
drug target with one or more components of the bacterium. Disadvantages of this 
approach include a lack of upfront knowledge regarding the mechanism of action of 
the drug and the need to identify the right in vitro growth conditions relevant for in 
vivo infections as metabolic targets behave differently depending on the composition 
of the growth medium. Several anti-mycobacterial compounds, which are currently in 
clinical development, have been discovered through whole cell-based screening 
methods. 
 
2.1.2 Recent successes using whole-cell screening approaches 
2.1.2.1 TMC207 
A whole-cell assay testing for inhibition of M. smegmatis and M. tuberculosis led to 
the discovery of a promising new diarylquinoline compound, TMC207, which acts on 
a novel target (Figure 2.1) (Andries et al., 2005). This compound displays high 
potency against M. tuberculosis and other mycobacterial species in vitro, but little 
activity against other bacteria and shows similar in vitro efficacy against drug-
sensitive and drug-resistant TB. The mechanism of action of TMC207 is different to 
that of fluoroquinolones and other quinolone classes, which target DNA gyrase 
(Andries et al., 2005). Comparative analysis of M. smegmatis and M. tuberculosis 
mutant strain sequences, resistant to TMC207 and the wild-type genome sequence, 
identified two point mutations (D32V and A63P) in the atpE encoding gene indicating 
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that the proton pump of ATP synthase is the target of TMC207 (Andries et al., 2005; 
Koul et al., 2007). Recent studies in Phase II clinical trials conducted with patients 
with MDR-TB taking TMC207 plus a standard background regimen have shown that 
the drug is safe and well tolerated (Matteelli et al., 2010); therefore TMC207 has the 
potential to be used as a front-line anti-TB agent. 
 
 
 
 
 
 
 
Figure 2.1. Structure of TMC207. 
 
2.1.2.2 DprE1 – the cellular target of benzothiaziones (BTZ) and 
dinitrobenzamides (DNB) 
Testing of sulfur-containing heterocycles for antibacterial activity led to the discovery 
of benzothiaziones (BTZ) (Figure 2.2) (Makarov et al., 2006). These highly potent 
compounds have very low MICs for M. tuberculosis and M. smegmatis and display 
high potency against MDR-TB strains (Pasca et al., 2010). Spontaneous mutant 
strains of M. smegmatis and M. tuberculosis with high-level resistance to BTZ were 
isolated and allowed comparative analysis against the wild-type genome sequence. 
This analysis identified MSMEG_6382 and Rv3790 as the drug target for M. 
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smegmatis and M. tuberculosis, respectively (Makarov, 2009). Rv3790 (dprE1) and 
its adjacent gene Rv3791 (dprE2) encode proteins which catalyse the epimerisation 
of decaprenyl-monophosphorylribose (DPR) into decaprenyl-
monophosphorylarabinose (DPA) (Figure 2.4) (Mikusová et al., 2005).  
 
 
 
 
 
 
Figure 2.2. Structure of BTZ043. The most advanced compound from the BTZ series. 
BTZ043 is a S enantiomer of BTZ038 which has a single chiral centre.  
 
 
An alternative whole-cell screening of compounds using high-throughput, 
fluorescence microscopy identified dinitrobenzamides (DNB) (Figure 2.3) as potent 
anti-TB inhibitors that also target DprE1 (Figure 2.4) (Christophe et al., 2009). 
 
 
 
 
 
Figure 2.3. Structure of DNB1. 
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The production of DPA is vital for arabinan synthesis as it is the only known 
precursor of polymerised Araf residues in mycobacteria and is therefore necessary 
for the formation of the complete cell wall (Mikusová et al., 2005; Wolucka, 2008). In 
addition, recent studies have identified DprE1, which is highly conserved in various 
actinobacteria including Corynebacterium glutamicum (Meniche et al., 2008), as an 
essential enzyme in M. smegmatis, suggesting it is essential across mycobacteria 
(Crellin et al., 2011) further validating DprE1 as a novel target for treatment of TB.  
 
Figure 2.4. BTZ and DNB targeting the DPA biosynthesis pathway. 
 
2.1.2.3 MmpL3 membrane protein 
Mycobacterial membrane protein large 3 (MmpL3) is an essential membrane 
transporter involved in the export of TMM and vital for formation of the cell wall 
(Varela et al., 2012). It has been identified as a common drug target of several 
chemically unrelated small molecules using comparative genomic analysis of 
spontaneous resistant mutants. These inhibitors include SQ109 (Tahlan et al., 2012), 
adamantyl urea (Grzegorzewicz et al., 2012), BM212 (La Rosa et al., 2012), THPP 
and spiro analogues (Remuiñán et al., 2013). A 1,2-diamine SQ109 (Figure 2.5), was 
discovered during an investigation of EMB derivatives and exhibits very high anti-
mycobacterial activity and potency against MDR-TB strains (Lee et al., 2003; 
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Protopopova et al., 2005). Recent success in Phase I and early Phase II clinical 
trials, where this compound was found to be safe and well tolerated, has highlighted 
SQ109 as a promising candidate as a future anti-TB agent (Sacksteder et al., 2012). 
 
 
 
Figure 2.5. Structure of SQ109. 
 
AU1235 (Figure 2.6) is a recently identified adamantyl urea displaying activity against 
M. tuberculosis (Grzegorzewicz et al., 2012). MmpL3 was identified as its cellular 
target when resistant mutants were found to harbour a single mutation in mmpL3 
(G758A) (Grzegorzewicz et al., 2012). Similarly, pyrrole derivative BM212 (Figure 
2.7) was shown to target the MmpL3 protein as all of the characterised mutants of  
M. smegmatis, M. bovis BCG, and M. tuberculosis H37Rv mutants harboured 
mutations in the mmpL3 gene (La Rosa et al., 2012).  
 
 
 
 
 
Figure 2.6. Structure of AU1235 - 1-(2-adamantyl)-3-(2,3,4-trifluorophenyl)urea. 
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Figure 2.7. Structure of pyrrole derivative BM212. 
A recent study has identified THPP and spiro analogues (Figure 2.8) as inhibitors 
against M. tuberculosis and M. bovis BCG through a high-throughput whole-cell 
screening campaign (Remuiñán et al., 2013).  
 
 
Figure 2.8. Structure of THPP 1 and Spiro 2.  
Chapter 2                                                                 Inhibitor targeting glycerol kinases 
42 
 
Subsequent whole genome sequencing of several M. tuberculosis resistant mutants 
identified single mutations in the mmpL3 gene (Remuiñán et al., 2013). Furthermore, 
experimental data has shown that treatment of M. bovis BCG with THPP and spiro 
resulted in the accumulation of TMM, thereby confirming MmpL3 protein as the 
cellular target for these compounds (Remuiñán et al., 2013). 
 
2.1.2.4 Pks13 – Cellular target of Thiophenes (TP) 
Recent studies have identified a class of compounds known as thiophenes (TP)  
(Figure 2.9) which cause mycobacterial cell death through the inhibition of M. 
tuberculosis polyketide synthase 13 (Pks13) a member of the type I polyketide 
synthase gene family (Wilson et al., 2013).  
Figure 2.9. Structure of  thiophenes TP2 and TP4. 
 
Isolated TP-resistant mutants were found to carry a single mutation (F79S) in close 
proximity to the catalytic Ser55 domain site in M. tuberculosis Pks13, which plays a 
critical role in the final condensation step in the assembly of mycolic acids (Portevin 
et al., 2004; Gande et al., 2004; Wilson et al., 2013). In vitro studies demonstrate TP 
inhibits the fatty acyl-AMP loading onto Pks13, preventing mycolic acids from being 
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fully synthesised (Wilson et al., 2013). The essentiality of Pks13 has been previously 
demonstrated in M. smegmatis, whilst in C. glutamicum, the pks13 deletion mutant is 
deficient in mycolic acids, but can still produce fatty acid precursors (Portevin et al., 
2004). Inhibiting Pks13 presents a new mechanism for mycolic acid synthesis 
inhibition that rapidly leads to mycobacterial cell death and therefore seems to be a 
promising target for developing future anti-TB drugs. 
 
2.1.2.5 QcrB – Cellular target of imidazo[1,2-a]pyridines (IP) 
More recently, high throughput whole-cell screening of an extensive compound 
library identified imidazo[1,2-a]pyridine (IP) compounds (Figure 2.10) as potent lead 
molecules active against M. tuberculosis and M. bovis BCG (Abrahams et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. Structure of compounds from imidazo[1,2-a]pyridines (IP) series. 
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Spontaneous resistant mutants of M. bovis BCG were generated against IP 1, 3, and 
4 and subsequent whole genome sequencing identified a single nucleotide 
polymorphism (T313A) in the qcrB gene, which encodes the b subunit of the 
cytochrome bc1 complex (Abrahams et al., 2012). The cytochrome bc1 complex is an 
integral membrane protein in the electron transport chain and is an important 
component of the bacterial respiratory system; therefore, the IP inhibitor family is a 
promising anti-TB agent (Abrahams et al., 2012).  
 
2.1.3 ChemBridge library 
The Tuberculosis Antimicrobial Acquisition and Coordination Facility (TAACF) has 
been formed to help researchers to develop new anti-TB drugs (Goldman and 
Laughon, 2009). One approach, which the Facility has initiated, is the development of 
high-throughput screening (HTS) systems, which have provided researchers with a 
powerful method for identifying in a short period of time, new lead compounds from a 
90,000 compound library from ChemBridge and consequently new drug targets 
(Ananthan et al., 2009). This information has been made available to researchers 
worldwide and provides an important basis for identifying active compounds as 
potential new leads as anti-tubercular drugs (Ananthan et al., 2009). Chemical 
compounds from the ChemBridge library (Ananthan et al., 2009) have been tested 
for anti-tubercular activity and their Minimum Inhibitory Concentration (MIC) to 
growing M. tuberculosis identified. A HTS approach was adopted to identify the 
cellular target of a compound from this library and the findings are presented in this 
Chapter. 
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2.2 Materials and Methods 
2.2.1 Bacterial strains and growth conditions 
Liquid cultures of M. smegmatis mc2155 strain were grown in Tryptic Soy Broth 
(TSB), soybean-casein digest medium (BD Difco) or Middlebrook 7H9 medium (BD, 
Difco) with 10% (v/v) oleic acid/albumin/dextrose/catalase (OADC) enrichment (BD, 
Difco), supplemented  with 0.05% (v/v) Tween-80 (Sigma-Aldrich) in a shaking 
incubator overnight at 37 °C. Liquid cultures grown in Middlebrook 7H9 medium 
contained either 0.25% (v/v) glycerol or 10 μM sodium acetate. For growth on plates, 
solid media were made with TSB, soybean-casein digest medium (BD, Difco) with 
addition of 1.5% (w/v) agar. Liquid cultures of E. coli were grown in Luria-Bertani (LB) 
broth in a shaking incubator overnight at 37 °C. For growth on plates, solid media 
were made with using Luria agar (Fisher Bioreagents). The concentration of the 
antibiotics used was 50 µg/ml kanamycin (Sigma-Aldrich) for E. coli and 25 µg/ml 
kanamycin for M. smegmatis. 
 
2.2.2 MIC determination 
Compounds AKR334, AKR849, AKR745, AKR986, AKR715 and AKR766 
(ChemBridge) were dissolved in 1 ml of dimethyl sulfoxide (DMSO). M. smegmatis 
culture was spread onto TSB plates containing 1 μg/ml, 2.5 μg/ml, 5 μg/ml, 10 μg/ml 
and 20 μg/ml concentrations of the each inhibitor. MIC was determined as the 
concentration of drug that reduced the number of colony-forming units (cfu) ml−1 by 
99%. 
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2.2.3 Generation of M. smegmatis spontaneous mutant resistant to AKR334 
M. smegmatis, grown to mid-log phase, was spread onto TSB plates containing the 
MIC of the AKR334 compound. Resistant colonies were picked after incubating for 
48 h at 37 °C and subsequently inoculated into liquid media in the absence of 
inhibitor. Putative mutants were grown to mid-log phase and selected on solid media 
containing 5× MIC of AKR334 to confirm the presence of a mutation conferring 
resistance to the inhibitor. Following validation of the mutant, the M. smegmatis 
spontaneous mutant and the M. smegmatis wild-type strains were inoculated in 
parallel into 50 ml TSB liquid media containing the MIC of the AKR334 compound (no 
compound for the wild-type), grown to late log phase and harvested by centrifugation 
for 10 min at 4000 rpm. Genomic DNA was extracted using the method described in 
Section 6.9. Purified genomic DNA from each M. smegmatis spontaneous mutant 
and the M. smegmatis wild-type was sent for whole-genome high-throughput 
sequencing using GS FLX Titanium Series (Roche) at the University of Birmingham. 
 
2.2.4 Construction of Recombinant Plasmids 
For overexpression of various M. smegmatis and M. tuberculosis glycerol operon 
genes in M. smegmatis, genes were amplified by PCR using Phusion High-Fidelity 
DNA polymerase (New England Labs) from M. smegmatis mc2155 and M. 
tuberculosis H37Rv genomic DNA using the oligonucleotide primers generated by 
Eurofins MWG Operon (Ebersberg, Germany) shown in Table 2.1. The PCR-
amplified DNA fragments of glpk1, glpk2, MSMEG_6757, MSMEG_6758 and RvglpK 
were cloned into the pMV261 vector containing a kanamycin resistance selection 
marker (Stover et al., 1991) using primer-incorporated restriction sites (restriction 
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endonucleases, New England Biolabs; T4 DNA ligase; New England Biolabs). All 
constructs were verified by DNA sequencing performed by Eurofins MWG Operon 
(Ebersberg, Germany). The constructs generated along with the empty pMV261 
vector were electroporated into M. smegmatis.  
 
Table 2.1. Oligonucleotide primers used for PCR of various M. smegmatis and M. 
tuberculosis glycerol operon genes. Restriction site is underlined. 
 
Oligonucleotide Restriction site Sequence (5’ → 3’) 
glpk1 forward BamHI ATTGCGGATCCAGTGACCGAGCGC 
glpk1 reverse ClaI TCGACATCGATTCACACGGTTTCG 
glpk2 forward EcoRI GCAGAATTCATGGCTGACTTCGTC 
glpk2 reverse HindIII ATAAGCTTCTCACTGGACGTCCAC 
MSMEG_6757 
forward 
BamHI ATTGCGGATCCAGTGCCAGGCACT 
MSMEG_6757 
reverse 
HindIII ATAAGCTTCTCACAGTTCCCGCCC 
MSMEG_6758 
forward 
BamHI ATTGCGGATCCAATGTCACGACGA 
MSMEG_6758 
reverse 
HindIII ATAAGCTTCTCAGACCGCGGATGC 
RvglpK forward EcoRI GCAGAATTCGTGTCCGACGCCATC 
RvglpK reverse HindIII ATAAGCTTCCTAGGACACGTCAAC 
 
2.2.5 Polar and apolar lipid extraction of [14C]-labelled inhibitor-treated 
cultures of M. smegmatis 
A 10 ml culture of M. smegmatis (wild-type and resistant mutant) was grown until 
mid-log phase (OD600 0.6). AKR334 was added to separate cultures at 0.5× MIC and 
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1× MIC and the culture grown for a further 4 hours at 37 °C. Cells were labelled with 
10 µCi ml−1 [1,2-14C]acetate (57 mCi mmol−1, GE Healthcare, Amersham Bioscience), 
and incubated at 37 °C overnight. The [1,2-14C]-labelled cells were harvested by 
centrifugation followed by washing with 2 ml phosphate buffer saline (PBS). Polar 
and apolar lipids were extracted using the method described in Section 6.10. 
Incorporation of [1,2-14C]acetate was quantified by liquid scintillation counting using 5 
% of the lipid fractions in 5 ml EcoScint A (National Diagnostics). The polar lipid 
extracts were examined by two dimensional thin-layer chromatography (2D-TLC) on 
aluminium-backed plates of silica gel 60 F254 (Merck 5554) by spotting equal counts 
of polar lipid extracts (50,000 cpm), which were then developed using solvent system 
D for polar lipids: CHCl3: MeOH: H2O (100:14:0.8) in the first direction and CHCl3: 
acetone: MeOH: H2O (50:60:2.5:3) in the second direction (Dobson et al., 1985). 
Polar lipids were visualised by 48 h exposure on X-ray films by autoradiography 
(Kodak Biomax MR film). 
 
2.3 Results and Discussion 
2.3.1 Identification of AKR334 as an inhibitor of M. smegmatis 
A number of chemical families from the ChemBridge library were screened for anti-
tubercular activity using an Alamar blue assay as part of a HTS campaign to discover 
new anti-mycobacterial agents (Ananthan et al., 2009; Maddry et al., 2009). We 
selected several compounds from the library (Figure 2.11) and tested for their MIC 
against M. smegmatis, as stated in Table 2.2. Amongst the compounds, N-benzyl-1-
(2,3-dimethoxybenzyl)-N-(2-phenylethyl)-4-piperidinamine oxalate (AKR334) 
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exhibited encouraging MIC values against M. smegmatis and thus was selected for 
use in strategies towards the identification of its target (Table 2.2).  
Figure 2.11. Compounds from the ChemBridge library active against M. tuberculosis. 
 
AKR334 had a MIC value of 5 µg/ml against M. smegmatis, which was very similar to 
its MIC against M. tuberculosis, reported as 6.32 µg/ml (Ananthan et al., 2009). 
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Antibacterial activity of this general chemical structure has not been previously 
reported in the scientific literature.  
Table 2.2. Minimum inhibitory concentration (MIC) values of compounds from 
ChemBridge library against M. tuberculosis and M. smegmatis. MIC against M. 
tuberculosis were tested previously (Ananthan, 2009; Maddry, 2009).  
MIC (µg/ml) 
Compound M. tuberculosis 
H37Rv 
M. smegmatis 
mc2155 
AKR334 6.32 5 
AKR849 3.02 >20 
AKR745 1.95 15 
AKR986 0.94 >20 
AKR715 5.13 >20 
AKR766 6.63 >20 
 
 
2.3.2 Identification of single nucleotide polymorphisms (SNPs) in a 
spontaneous resistant mutant 
As AKR334 had an encouraging MIC value against M. smegmatis, this bacterium 
was established as a suitable model for target identification. M. smegmatis 
spontaneous resistant mutants were generated against the MIC of the compound. 
Selected mutant colonies continued to show growth on plates containing 15 µg/ml, 20 
µg/ml and 50 µg/ml concentrations of the molecule, which showed they were highly 
resistant to AKR334. A resistant mutant was selected and sent for whole-genome 
sequencing to identify any mutations within the genes which might allow the resistant 
bacteria to survive in the presence of the inhibitor. The genome sequence of the 
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resistant mutant was aligned with the genome sequence of the wild-type to identify 
the Single Nucleotide Polymorphisms (SNPs) potentially responsible for drug 
resistance, which were filtered to exclude indels and low frequency variants. The 
remaining SNPs are shown in Table 2.3.  
 
Table 2.3. Single nucleotide polymorphisms detected in M. smegmatis spontaneous 
mutants resistant to AKR334.  
 
Gene position Gene product Nucleotide base 
change 
Amino acid 
change 
281479 mmpL3 A to G F649L 
282457 mmpL3 C to T V323I 
6802897 None* G to T* None* 
*Base substitution is located in the non-coding region.  
 
Whole-genome sequencing revealed two base change mutations in the mmpL3 
gene, which encodes for the MmpL3 protein. These mutations were at codon 649 
(AAG>GAG) and at codon 323 (CAG>TAG). The identified point mutations would 
result in the following changes in the protein sequence: phenylalanine at position 649 
to leucine and valine at position 323 to isoleucine. Multiple protein sequence 
alignment of mmpL3 orthologues shows that both these point mutations occur in 
amino acid residues conserved across various mycobacteria (Figure 2.12). As 
mentioned above, MmpL3 protein has recently been established as the cellular target 
of several drugs (La Rosa et al., 2012; Tahlan et al., 2012; Grzegorzewicz et al., 
2012; Remuiñán et al., 2013).  
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Figure 2.12. Multiple protein sequence alignment of mmpL3 orthologues in different 
mycobacteria. Numbers indicate the amino acid co-ordinates of each protein. Conserved 
residues are highlighted in light blue. Dash indicates gap in amino acid sequence. Red 
arrows indicate position of SNP detected in the AKR334-resistant M. smegmatis mutant.  
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A single base change mutation (A to G) was also detected at the genomic position 6802897. 
The sequence in this region does not encode amino acids; however, this region is the 
promoter sequence for the glycerol operon (Figure 2.13), a cluster of genes which 
are involved in glycerol uptake and metabolism. 
 
Figure 2.13. Genetic organisation of the glycerol operon cluster in M. smegmatis and 
M. tuberculosis. Red arrow indicates position of SNP in the AKR334-resistant M. 
smegmatis mutant. 
 
In M. smegmatis, MSMEG_6756 (glpK1) and MSMEG_6759 (glpK2) genes encode 
glycerol kinases. These enzymes convert incoming glycerol into glycerol-3-
phosphate via the transfer of a phosphate from ATP to glycerol, thus catalysing the 
following reaction: ATP + glycerol <=> ADP + sn-glycerol 3-phosphate (Titgemeyer et 
al., 2007). While M. smegmatis possesses two glycerol kinases, by contrast, M. 
tuberculosis has just one glycerol kinase encoded by Rv3696c (RvglpK), which 
shows high similarity to those in M. smegmatis (55% protein identity for 
MSMEG_6756 and 77% protein identity for MSMEG_6759). In M. smegmatis, 
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MSMEG_6761, part of the glycerol operon gene cluster, codes for a glycerol-3-
phosphate dehydrogenase. This shares 56% protein identity with glycerol-3-
phosphate dehydrogenase encoded by glpD2. The M. smegmatis glycerol operon 
also includes MSMEG_6757 and MSMEG_6758 genes, which encode a glycerol 
operon regulatory protein and a glycerol transport protein, respectively. However, a 
BLAST search did not identify any similar proteins in M. tuberculosis.  
 
2.3.3 Over-expression of glycerol operon genes in M. smegmatis 
To identify whether or not any of the proteins, which comprise part of the M. 
smegmatis glycerol operon were the cellular target of AKR334, the glycerol kinase 
(MSMEG_6756 and MSMEG_6759), the glycerol operon regulatory protein 
(MSMEG_6757), glycerol transport protein (MSMEG_6758) and glycerol kinase 
(Rv3696c) from M. tuberculosis were overexpressed in M. smegmatis using the 
expression plasmid vector pMV261 (containing a kanamycin resistance selection 
marker) and the MIC of AKR334 inhibitor was reassessed. The pMV261 vector exerts 
approximately 5 times copy number. Additionally, when an empty pMV261 vector 
was electroporated into M. smegmatis and tested against AKR334, the MIC 
increased from 5 µg/ml to 8 µg/ml; therefore, the presence of kanamycin increases 
the MIC of AKR334 inhibitor in M. smegmatis. All constructs were successfully 
electroporated into M. smegmatis, except for pMV261-MSMEG_6758 which did not 
yield any colonies. Successful transformants of the remaining constructs were grown 
in liquid culture and spotted onto plates containing the MIC of AKR334 inhibitor in the 
presence of kanamycin. However, none of the recombinant strains was able to grow 
at the MIC value. Over-expression of the glycerol operon genes did not increase the 
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MIC of AKR334 inhibitor; as a result we could not determine that whether or not 
these genes were the drug target. 
 
2.3.4 MmpL3 protein is not the cellular target of AKR334 
As previously described, spontaneous mutants resistant to SQ109 (Tahlan et al., 
2012), adamantyl ureas (Grzegorzewicz et al., 2012) and pyrrole BM212 (La Rosa et 
al., 2012), compounds with known anti-TB activities, were shown to contain 
mutations in the mmpL3 gene. Studies have shown that MmpL3 protein is involved in 
the transport of TMMs across the cell wall where they are then converted to TDMs 
(Varela et al., 2012). Experiments where bacilli were exposed to SQ109 and 
adamantyl ureas led to the accumulation of TMM, thus proving MmpL3 protein is the 
cellular target of these inhibitors (La Rosa et al., 2012; Tahlan et al., 2012). Recent 
studies have used this method to show that THPP and spiro analogues target the 
MmpL3 protein (Remuiñán et al., 2013). To address the putative role of MmpL3 in 
TMM export, we assessed the effects of increasing concentrations of AKR334 on 
lipid metabolism in M. smegmatis. Cultures of the wild-type and AKR334-resistant M. 
smegmatis strains were grown in broth in the presence (0.5× MIC and 1× MIC) or 
absence of inhibitor for 4 hours, then labelled with [1,2-14C]acetate overnight and 
then subjected to a lipid extraction procedure. In wild-type M. smegmatis [1,2-
14C]acetate-labelled cultures, TMM levels remained the same in cultures grown in the 
absence of inhibitor and cultures grown in increasing concentrations of AKR334 
inhibitor, suggesting MmpL3 protein is not the cellular target (Figure 2.14). However, 
AKR334-resistant [14C]-labelled cultures, grown in increasing concentrations of 
AKR334 inhibitor, showed an accumulation of TDM. 
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Figure 2.14. 2D-TLC analysis of [1,2-14C]acetate-labelled lipids from wild-type and 
AKR334-resistant M. smegmatis strains in the presence of AKR334 inhibitor. Cultures 
were grown in the absence and presence of AKR334 inhibitor (0.5 × MIC and 1 × MIC) for 4 
hours, and then and labelled using [1,2-14C]acetate overnight. Equal counts of polar lipid 
extracts (50,000 cpm) were applied to TLC plates which were developed using solvent 
system D for polar lipids: CHCl3:CH3OH:H2O (100:14:0.8) in the first direction and CHCl3: 
acetone: MeOH: H2O (50:60:2.5:3) in the second direction. Polar lipids were visualised by 48 
h exposure on X-ray films by autoradiography (Kodak Biomax MR film).  
 
2.3.5 AKR334 displays greater inhibitory activity in the presence of glycerol as 
a carbon source 
Recent studies have identified frame-shift mutations in glpK in spontaneous mutants 
of inhibitors against M. tuberculosis, indicating their mechanism of action is linked to 
glycerol metabolism (Pethe et al., 2010; Stanley et al., 2012). Pyrimidine-imidazoles 
(PI) are a novel class of compounds which kill bacilli by inducing self-poisoning of M. 
tuberculosis through accumulation of glycerol phosphate and rapid ATP depletion 
(Pethe et al., 2010). However, these compounds have shown no efficacy in animal 
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models of TB (Pethe et al., 2010).  The A039 compound ((1-(4-ethoxyphenyl)-2-(4-
methoxyphenyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-1-ium chloride) was 
shown to have greater inhibitory activity against M. tuberculosis grown on media 
containing glycerol as a sole carbon source compared to media containing acetate. 
To conﬁrm that the observed activity of AKR334 against M. smegmatis is dependent 
upon growth in glycerol-containing media, we compared the activity of AKR334 
against M. smegmatis grown in liquid media containing glycerol or acetate as the 
sole carbon source. M. smegmatis was grown in the following concentrations of 
AKR334 inhibitor: 8 µg/ml, 10 µg/ml and 14 µg/ml. Cultures were incubated at 37 °C 
and the OD600 was measured after 24 hours. The OD600 of M. smegmatis culture 
grown in the absence of the inhibitor was also measured and this was used to 
calculate the percentage of bacterial killing at each drug concentration (Figure 2.15). 
The inhibitory activity of AKR334 was higher in M. smegmatis cultures grown in the 
presence of glycerol compared to those cultures grown in the presence of acetate. 
The activity of AKR334 inhibitor was dependent on the presence of glycerol as a sole 
carbon source. 
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Figure 2.15. Percentage of bacterial killing of M. smegmatis in liquid media containing 
varying concentrations of compound AKR539 with acetate or glycerol as the carbon 
source. M. smegmatis cultures were grown in varying concentrations of AKR334 inhibitor 
with liquid media containing glycerol or acetate as the sole carbon source and incubated at 
37 °C. OD600 was measured after 24 hours. The OD600 of M. smegmatis culture grown in the 
absence of the inhibitor was also measured and this was used to calculate the percentage of 
bacterial killing at each drug concentration. 
 
2.4 Conclusion 
In this Chapter, compounds, which have previously been identified to possess 
inhibitory activity against M. tuberculosis were screened against M. smegmatis which 
has a comparatively faster generation time and can be handled without BSL-3 
facilities. Spontaneous resistant mutants were generated against AKR334, a 
compound which displayed an encouraging MIC value against M. smegmatis. 
Through the alignment of the whole-cell genomic sequence of parental and AKR334-
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resistant M. smegmatis strains, SNPs were found in the mmpL3 gene and the 
promoter sequence of the glpK genes. 
 
Previous studies have demonstrated that MmpL3 specifically plays an essential role 
in mycolic acid transport and that depleting the mmpL3 gene in a conditional mutant 
resulted in the intracellular accumulation of TMM (Varela et al., 2012). These results 
are supported by mmpL3-inhibitor related studies where it was observed that 
inhibition of mmpL3 resulted in TMM accumulation (La Rosa et al., 2012; Tahlan et 
al., 2012; Remuiñán et al., 2013). However, in our study, when cells were treated 
with AKR334, there was no difference in the levels of TMM compared to untreated 
cells whereas. This ruled out the MmpL3 protein as the cellular target of AKR334. 
 
In a parallel experiment, genes from the glycerol operon cluster in M. smegmatis and 
the glpK gene from M. tuberculosis were overexpressed in M. smegmatis using the 
mycobacterial vector pMV261, which exerts approximately 5 times copy number. 
However, overexpression of these genes did not lead to any change in tolerance to 
AKR334. Therefore, from this experiment, we were unable to determine whether the 
glpK genes were the drug target of AKR334. 
 
We also tested the hypothesis that the mechanism of action of AKR334 is related to 
the metabolism of different carbon sources. When M. smegmatis cells were treated 
with AKR334 in the presence of glycerol, there was a higher percentage of bacterial 
killing after 24 hours compared to those cells grown in the presence of acetate. This 
indicates that the mode of action of AKR334 is possibly associated with glycerol 
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metabolism. Recently, the mechanisms of action of inhibitors against M. tuberculosis 
have been shown to be linked to glycerol metabolism (Pethe et al., 2010; Stanley et 
al., 2012). PI inhibitors were demonstrated to induce self-poisoning in M. tuberculosis 
by stimulating the accumulation of glycerol phosphate and leading to rapid depletion 
of ATP, which leads to poisoning of the cells, have been identified (Pethe et al., 
2010). Therefore, further work using experiments to analyse glycerol phosphate 
levels in AKR334-treated cells could to done to determine whether AKR334 works in 
the same way as PI inhibitors. In addition to this, we could conduct a comparative 
analysis of the transcription of the glpK genes in the parental and AKR-resistant 
mutant strains using Reverse Transcription PCR. This would allow us to examine 
whether there is a difference in the expression of these genes and help identify the 
mode of action of AKR334. 
 
In conclusion, this Chapter sums up the identification of a new inhibitor which 
possibly causes killing of M. smegmatis via toxic poisoning through the accumulation 
of glycerol phosphate and ATP depletion. Further studies are needed to confirm the 
mechanism of action of AKR334.  
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3.1 Introduction 
3.1.1 Immunomodulatory properties of LM and LAM 
LAM and related lipoglycans are not only essential for mycobacterial growth and 
survival (Haites et al., 2005; Kovacevic et al., 2006), but are also thought to play 
important roles in the modulation of the host response during infection. During the 
last decade, investigators have isolated LAM and LM from a range of mycobacteria 
with various capping motifs to investigate the broad spectrum of immunomodulatory 
activities displayed by these complex polysaccharides and to gain insight into the 
nature of these host-pathogen interactions. 
 
The ability of mycobacteria to survive within the hostile environment of host 
macrophages is central to the disease and is made possible through several 
strategies. These include manipulation of the phagosome to prevent maturation 
(Armstrong and Hart, 1971; Russell, 2001; Nguyen and Pieters, 2005) and 
suppression of the cell-mediated host immune response after infection. Several 
studies have demonstrated that lipoglycans have a major role in both of these 
phenomena. The nature of these immunomodulatory responses is determined by the 
accessibility of lipoglycans with different receptors of the immune system, such as 
TLR-2 and C-type lectins. 
 
3.1.1.1 Phagosome maturation arrest 
As described before (section 1.3), M. tuberculosis bacilli are able to persist within 
macrophages by preventing the fusion of phagosomes with lysosomes, a process 
Chapter 3                                                                Essentiality of PPM synthase 
63 
 
that would normally lead to killing and digestion of the pathogen in an acidic 
environment (Armstrong and Hart, 1971; Russell, 2001; Nguyen and Pieters, 2005). 
ManLAM has been demonstrated to play a role in the inhibition of phagosome 
maturation (Figure 3.1) (Vergne et al., 2003). During infection, the phagosome-
lysosome fusion process is initiated through an increase in concentration of cytosolic 
Ca2+. ManLAM inhibits this uptake of Ca2+, thus blocking the successive steps of PI3-
hVPS34 kinase activity at the phagosomal membrane (Malik et al., 2001; Vergne et 
al., 2004; Vergne et al., 2004; Chua and Deretic, 2004). Normally in this process, 
PI3-kinase alongside its modulatory subunit p150 will lead to the production of the 
membrane-trafficking lipid phosphatidylinositol 3-phosphate (PI3P) which 
subsequently mediates the recruitment of Rab 5 effector early endosome autoantigen 
1 (EEA1) to the phagosome (Vergne, Chua, et al., 2004). EEA1 is necessary for the 
delivery of cathepsins (lysosomal hydrolases) and VOH
+ ATPase from the trans-Golgi 
network to the phagosome via interaction with syntaxin-6, soluble NSF attachment 
protein receptor (SNARE) protein (Simonsen et al., 1999).   
 
The exact mechanism by which ManLAM modulates Ca2+ fluxes is unknown. It has 
been suggested that ManLAM activates the macrophage phosphatase SHP-1 
leading to the impairment of Ca2+ signalling (Vergne, Chua, et al., 2004). It has also 
been reported that ManLAM may cause phagosome maturation arrest by activating 
p38 mitogen-activated protein kinase (p38 MAPK), a mechanism distinct from 
blocking the rise of cytosolic Ca2+. Furthermore, ManLAM has been implicated as a 
trigger for an increase in p38 MAPK activation, leading to modulation of EEA1 
recruitment (Fratti, Chua, and Deretic, 2003). However, recent experiments have 
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shown that isolated ManLAM does not influence p38 MAPK activation (Welin et al., 
2008).  
Figure 3.1. The role of ManLAM and PIMs in phagosome maturation arrest in 
mycobacteria. ManLAM inhibits lysosomal fusion and acidification by inhibiting cytosolic-
Ca2+ increase and thereby blocks the successive steps of hVPS34 kinase activity, the 
recruitment of Rab5, EEA1 and Syn6, and the delivery of cathepsins and VoH+ ATPase to 
the phagosome. PIMs induce the fusion of the phagosome with early endosomes to promote 
delivery of nutrients to the bacteria; this mechanism is dependent on Rab5. CaM, 
Calmodulin; EEA1, Early endosome autoantigen; MMR, Macrophage mannose receptor; 
PI3P, Phosphatidylinositol 3-phosphate; Syn, Syntaxin; TGN, trans-Golgi network. Adapted 
from Mishra et al., (2011). 
 
As well as ManLAM, PIMs and LM have also been investigated for their possible role 
in affecting phagosome maturation. LM does not interfere with phagolysosomal 
development (Kang et al., 2005). However, similarly to LAM, PIMs appear to be 
involved in this process via incorporation into lipid rafts (Vergne et al., 2004), which 
are cholesterol and glycosphingolipid-rich domains that are associated with cell 
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signalling processes, thereby competitively inhibiting insertion of LAM (Welin et al., 
2008). PIMs appear to stimulate the fusion of phagosomes with early endosomes to 
provide nutrients to mycobacteria residing in the phagosome (Figure 3.1) (Kelley and 
Schorey, 2003; Vergne et al., 2004). Although PIMs seem to have the opposite to the 
effect of LAM, which prevents endosomal fusion, they are also involved in the 
inhibition of phagosome acidification by inducing recruitment of syntaxin-4 and the 
transferrin receptor (involved in iron delivery) (Fratti et al., 2003; Vergne et al., 2004; 
Vergne, et al., 2004).  
 
 
Despite their differences in the influence of phagosome maturation, both ManLAM 
and PIMs may be involved in recognition by the mannose receptor (MR) (Vergne et 
al., 2004). Recent studies have demonstrated that MR has a higher affinity to higher-
order PIMs (e.g. PIM5 and PIM6) than to lower-order PIMs (i.e. PIM2), which are not 
recognised (Torrelles et al., 2006). 
 
3.1.1.2 Cluster of differentiation (CD)1 glycoproteins 
Cluster of differentiation (CD)1 glycoproteins are related to major histocompatibility 
complex (MHC) class I and II molecules, which are important antigen-presenting 
molecules of the immune system.  While MHC class I and II molecules are 
responsible for presenting peptide antigens to T-cells, CD1 glycoproteins have been 
identified to present glycolipids to CD1-restricted T cells (Young and Moody, 2006; 
De Libero and Mori, 2010). Therefore, in mycobacterial infection, exposure to unique 
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glycolipids of the mycobacterial cell wall differentially elicits CD1-restricted innate and 
adaptive T-cell responses (Porcelli et al., 1998; Barral and Brenner, 2007).  
 
The CD1 family can be categorised into three groups: group 1 includes CD1a, CD1b 
and CD1c; group 2 includes CD1d; and group 3 includes CD1e (Barral and Brenner, 
2007). From these CD1 molecules, CD1b and CD1d have been identified as binding 
and presenting PIMs and related lipoglycans. While CD1b can bind to PIM2 and 
ManLAM (Fischer et al., 2004; Zajonc et al., 2006), CD1d can only bind to lower-
order PIMs, including PIM2 and PIM4, but not LM or ManLAM (Sieling et al., 1995; 
Prigozy et al., 1997; Ernst et al., 1998).  
 
Recent studies have shown that mycobacteria have the ability to impair the function 
and expression of CD1 molecules and in doing so, provide a way to evade the host 
immune response (Gagliardi et al., 2007; Gagliardi et al., 2009). For example, α-
glucan has been demonstrated to induce monocyte differentiation into dendritic cells, 
thereby blocking the expression of CD1 molecules and preventing them from 
presenting lipid antigens to CD1-restricted T-cell clones (Gagliardi et al., 2007). 
 
3.1.1.3 Toll-like receptors (TLR) 
TLRs have been demonstrated to play a role in the recognition of mycobacterial 
pathogens (Quesniaux, Fremond, et al., 2004; Jo, 2008). Although lipoproteins are 
the major ligands for TLR2 (Brightbill et al., 1999), MPI-anchored mannosylated 
lipoglycans can also signal via TLR2, depending on their degree of acylation and 
mannosylation (Gilleron et al., 2006; Doz et al., 2007; Nigou et al., 2008). For 
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example, there is a positive correlation between mannan chain length and the ability 
of the lipoglycan to activate TLR2 (Nigou et al., 2008). LM, has been shown to be a 
potent inducer of TLR2-signalling (Quesniaux et al., 2004); however, this activity is 
limited to the tri- and tetra-acylated forms (Ac3LM and Ac4LM, respectively) (Gilleron 
et al., 2006; Doz et al., 2007). Studies have reported that in comparison to 
Ac1/Ac2PIM6 and LM, Ac1/Ac2LAM, PILAM and AraLAM were shown to be poor 
inducers of TLR2 (Nigou et al., 2008). Recently, this was demonstrated in an 
experiment where LAM comprising a truncated arabinan domain from a M. 
smegmatis AftC knock-out mutant showed enhanced TLR2-signalling compared to 
wild-type LAM (Birch et al., 2010). This indicates the arabinan domain prevents 
proper interaction of LAM with TLR2 (Vignal et al., 2003).  
 
3.1.1.4 DC-SIGN  
The interaction of mycobacteria and dendritic cells (DC) is largely mediated by a C-
type lectin receptor called dendritic cell-specific intercellular adhesion molecule-3 
(ICAM-3) grabbing nonintegrin (DC-SIGN) (Tailleux et al., 2003). While the exact role 
of DC-SIGN in mycobacterial infection is unclear, it has been reported that ManLAM 
interacts with DC-SIGN to prevent DC maturation, thereby suppressing the immune 
response (Geijtenbeek et al., 2003).  
 
As well as only recognising LAM that is mannose-capped (Geijtenbeek et al., 2003; 
Maeda et al., 2003), DC-SIGN has a stronger affinity to increasing α(1→2)-linked 
Manp residue chain length (Koppel et al., 2004). Thus, higher-order PIMs, including 
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PIM5 and PIM6, are recognised by DC-SIGN with a higher affinity than are lower-
order PIMs (Boonyarattanakalin et al., 2008; Driessen et al., 2009).  
 
Although DC-SIGN is thought to be a vital uptake receptor to infect DCs, recent 
studies have demonstrated that ManLAM binding to lipopolysaccharide-activated 
DCs leads to a rise in the secretion of proinflammatory IL-12 and IL-6 as well as IL-
10 (Gringhuis et al., 2009). Therefore, it may be possible that DC-SIGN signalling 
may function primarily in the protection of the host (Ehlers, 2010). 
 
3.1.1.5 Mannose receptor (MR) 
In addition to complement receptors, mannose receptors (MR), a type I 
transmembrane monomeric C-type lectin, are important mediators for phagocytic 
uptake of mycobacteria by macrophages (Schlesinger, 1993). For example, a recent 
study has shown that binding of ManLAM to MR during phagosomal development is 
a key step in inhibition of fusion with lysosomes (Kang et al., 2005). That MR only 
binds ManLAM and not AraLAM or PILAM, shows that the presence of a mannose 
cap on ManLAM is essential for the recognition by the MR (Schlesinger et al., 1994). 
This observation further demonstrates that the macrophage MR is necessary for 
blocking phagosome maturation, a step which is more prevalent in virulent strains of 
mycobacteria (Kang et al., 2005). Unsurprisingly, MR binds PIM5 and PIM6, with a 
preference for the tri-acylated species rather than the tetra-acylated, but not to lower-
order PIM2, LM and AraLAM or PILAM (Schlesinger et al., 1994; Villeneuve et al., 
2005; Torrelles et al., 2006). The macrophage MR has also been implicated in the 
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delivery of LAM to the late endosomal compartments for loading on to CD1b 
molecules, thus inducing T-cell immune response (Prigozy et al., 1997). 
 
3.1.2 Biosynthesis of PIMs, LM and LAM 
Deciphering the biosynthetic pathway of PIMs, LM and LAM has been central to 
biochemical and genetic studies in recent times. These studies have proposed the 
following model for PIM biosynthesis: PI→PIM2→ PIM4→ PIM6. Glycosylation of PI is 
sequentially catalysed by the α-mannopyranosyltransferases PimA, PimB‟, PimC and 
PimE and occurs on the cytosolic face of the plasma membrane (Figure 3.2) (Besra 
and Brennan, 1997; Morita et al., 2006; Mishra et al., 2011). In the first step of the 
pathway, PimA (Rv2610c), an enzyme of the GT-B superfamily, catalyses the 
addition of a Manp residue, using GDP-mannose as the donor to position O-2 of PI to 
generate PIM1 (Korduláková et al., 2002; Guerin et al., 2007) which is subsequently 
acylated by Rv2611c at the 6-position of the Manp residue (Korduláková et al., 
2003). The acyltransferase role of Rv2611c was determined in a study where a 
Rv2611c mutant of M. smegmatis exhibited severe growth defects and accumulated 
non-acylated PIM1 and PIM2 (Korduláková et al., 2003). A second mannosylation 
step, catalysed by PimB‟ (Rv2188c), introduces another Manp residue at position O-6 
of PI to produce Ac1/ Ac2PIM2 (Mishra et al., 2008). Initially, this reaction was thought 
to be performed by PimB (Rv0557c) (Schaeffer et al., 1999); however, it was 
subsequently shown that disruption of this gene had no effect on Ac1PIM2 
biosynthesis in M. tuberculosis (Torrelles et al., 2009). However, deletion of PimB‟ in 
C. glutamicum resulted in a mutant devoid of Ac1/Ac2PIM2 and accumulation of 
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Ac1PIM1, thereby confirming the α-D-mannose-α(1→6)-phosphatidyl-myo-inositol-
mannopyranosyltransferase activity of PimB‟ (Mishra et al., 2008).  
 
Figure 3.2. Pathway of biogenesis of phosphatidyl-myo-inositol mannosides, 
lipomannan and lipoarabinomannan biosynthesis in M. tuberculosis. PI is glycosylated 
by PimA, PimB' (Guerin et al., 2007; Guerin et al., 2009) and acylated by Rv2611c to form 
AcPIM2 (Korduláková et al., 2003), which is further mannosylated by PimC or possibly PimD 
to form AcPIM4 (Mishra et al., 2011). AcPIM4 is probably transported to the extracytoplasmic 
side by an unidentified flippase and further mannosylated by PimE and/or another 
unidentified enzyme to form AcPIM6 (Morita et al., 2006). AcPIM4 is sequentially extended by 
MptB, MptA and MptC resulting in lipomannan (Mishra et al., 2007; Mishra, Alderwick, et al., 
2008; Mishra, Krumbach, et al., 2011). Lipomannan is then primed by an unidentified 
arabinofuranosyltransferase, which is extended by EmbC, AftD and AftC to form Ara-4 or 
branched Ara-6 (Birch et al., 2008; Skovierová et al., 2009; Birch et al., 2010), while AftB 
terminates the chain to form LAM (Seidel et al., 2007). LAM is capped by CapA and Rv2181 
(MptC) to form ManLAM (Dinadayala et al., 2006). GDP, Guanosine diphosphate; LAM; 
Lipoarabinomannan; LM, Lipomannnan; ManLAM, Mannosyl-lipoarabinomannan; PI, 
Phosphatidylinositol; PIM, Phosphatidyl-myo-inositol. Manp, Mannopyranose; Araf, 
Arabinofuranose. Adapted from Jankute et al., (2012). 
 
Biochemical studies of the M. tuberculosis CDC1551 strain led to the identification of 
RvD2-ORF1 as the mannosyltransferase PimC with Ac1PIM2: α-D-mannose-α(1→6)-
phosphatidyl-myo-inositol-mannopyranosyltransferase activity, responsible for the 
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addition of a Manp residue to the 6-OH of mannose at the non-reducing end of 
Ac1/Ac2PIM2, to form Ac1/Ac2PIM3 (Kremer et al., 2002). This was demonstrated in a 
study in which a cell-free assay containing GDP-[14C] mannose, amphomycin (an 
antibiotic that inhibits the PPM synthase) and membranes from M. smegmatis 
overexpressing PimC led to the synthesis of Ac1/Ac2PIM3 (Kremer et al., 2002). The 
addition of a Manp residue from GDP-mannose to the 6-OH of mannose at the non-
reducing end of Ac1/Ac2PIM3 to generate Ac1/Ac2PIM4 is catalysed by either an 
unknown α(1→6)-mannopyranosyltransferase (PimD) or PimC itself (Mishra et al., 
2011). While mannosyltransferases utilising nucleotide-derived sugar donors are 
employed in the mannosylation steps leading to this point, from here on 
mannosyltransferases from the GT-C superfamily utilising polyprenylphosphate-
based mannosyl donors are used for elongation and branching of LM and LAM (Liu 
and Mushegian, 2003; Guerin et al., 2010).  
 
From Ac1/Ac2PIM4, the biosynthetic pathway diverges into two branches: one leads 
to the formation of Ac1/Ac2PIM6, whereas the other leads to the formation of LM and 
LAM. PimE (Rv1159), a recently identified α(1→2)-mannopyranosyltransferase, 
utilises the polyprenylphosphate sugars PPM/C50-P-Man as a donor to add an 
α(1→2)-Manp residue to Ac1/Ac2PIM4 in the synthesis of Ac1/Ac2PIM5 (Morita et al., 
2006). A successive α(1→2)-Manp residue is added on to Ac1/Ac2PIM5 to produce 
Ac1/Ac2PIM6. Although the putative glycosyltransferase responsible for this last 
reaction is currently uncharacterised, it is thought to be encoded by Rv0051 or 
Rv0541 (Liu and Mushegian, 2003; Berg et al., 2007). While PimE directs 
Ac1/Ac2PIM4 towards Ac1/Ac2PIM6 production, the LpqW channel, which M. 
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smegmatis regulates the amount of higher PIMs and lipoglycans, is thought to 
channel Ac1/Ac2PIM4 towards LM synthesis (Kovacevic et al., 2006; Crellin et al., 
2008). It has also been hypothesised that Ac1/Ac2PIM4 is transported across the 
plasma membrane, by unidentified flippases to become available for further 
mannosylation by PimE (Liu and Mushegian, 2003; Mishra et al., 2008). 
 
In the second branch of the pathway, Ac1/Ac2PIM4 is hypermannosylated by 
glycosyltransferases of the GT-C superfamily leading to synthesis of LM. Recent 
studies have demonstrated that MptA (Rv2174) and MptB (Rv1459c), orthologue of 
two α(1→6)-mannopyranosyltransferases in C. glutamicum,  are involved in the 
synthesis of the mannan backbone (Mishra et al., 2007; Kaur et al., 2007). While 
MptA synthesises the distal end of the α(1→6) mannan core of LM,  MptB catalyses 
the synthesis of the proximal end through the addition of 12–15 Manp residues to the 
backbone (Mishra et al., 2007; Kaur et al., 2007). A decrease in α(1→6)-
mannopyranosyltransferase activity and the absence of LM and LAM, was observed 
in a MptB-deletion mutant in C. glutamicum. Furthermore, cell-free C. glutamicum 
assays using C50-P-Manp and expressing Rv1459c and/or its M. smegmatis 
homologue MSMEG_3120 further indicated that these enzymes possess α(1→6)-
mannopyranosyltransferase activity. MptC (Rv2181) is responsible for further 
decorating the α(1→6)-mannan core with a single α(1→2)-Manp residue to the side 
chains of LM (Mishra et al., 2011).  
 
The transition of LM and LAM is thought to involve the initial priming of LM by a few 
Araf units from the sugar donor decaprenylphosphate arabinan (DPA) in a similar 
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fashion to how the galactan portion of AG is primed by AftA (Alderwick et al., 2006; 
Wolucka, 2008). However, the enzyme responsible for this function is 
uncharacterised. EmbC (Rv3793) is then responsible for further extension of the 
primed Araf-LM, namely the addition of 12-16 α(1→5)-Araf residues (Zhang et al., 
2003; Birch et al., 2010). AftC (Rv2673) has been demonstrated to catalyse the 
addition of the α(1→3)-Araf branch points in LAM (Birch et al., 2010), in a similar 
manner to AG (Birch et al., 2008). More recently, studies have proposed a second 
α(1→3)-arabinofuranosyltransferase called AftD (Rv0236c) through experiments 
based on artificial chemical acceptors on crude membrane extracts from M. 
smegmatis (Skovierová et al., 2009); however, as a viable deletion mutant of this 
enzyme with a clear phenotype could not to be generated, the role of AftD is 
debatable (Skovierová et al., 2009). AftB (Rv3805c) is likely to be responsible for 
terminating the arabinan domain in LAM synthesis (Seidel et al., 2007). Although 
AftB has also been shown to have β(1→2)-arabinofuranosyltransferase activity in the 
synthesis of AG (Seidel et al., 2007), it is possible as observed with AftC that this 
enzyme has dual functionalities in both AG (Birch et al., 2008) and LAM (Birch et al., 
2010).  
 
The homologue of Rv1635c in M. tuberculosis CDC1551 was identified as a 
glycosyltransferase possibly involved in ManLAM capping (Dinadayala et al., 2006). 
Deletion mutants of homologues of Rv1635c in M. marinum and M. bovis BCG 
identified this gene as a PPM-dependent α(1→5)-mannopyranosyltransferase termed 
CapA, which adds the first Manp residue on to the non-reducing arabinan termini of 
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LAM (B.J. Appelmelk et al., 2008). In M. tuberculosis, MptC (Rv2181) has been 
characterised as a PPM-dependent α(1→2)-mannosyltransferase that plays a bi-
functional role in LAM biosynthesis; while it is involved in branching LM, it is also 
involved in the capping of LAM with α(1→2)-Manp residues at the non-reducing end 
of LAM (Mishra et al., 2011). 
 
3.1.3 Polyprenyl monophosphomannose synthase (PPM synthase) encoded 
by Ppm1 
Comparative studies with known dolichol-monophosphomannose (DPM) synthases 
led to the identification of Mt-Ppm1 (Rv2051c) in M. tuberculosis (Gurcha et al., 
2002). Experimental studies conducted in vitro have demonstrated that Mt-Ppm1 
generates a key PPM sugar donor that utilises GDP-Man and C50/C35-polyprenol 
phosphates as substrates, similar to DPM synthase (Gurcha et al., 2002). Although 
highly conserved within bacterial species, studies have identified subtle alterations in 
the organisation of the ppm1 locus across mycobacteria (Gurcha et al., 2002).  In M. 
tuberculosis, the well characterised Mt-ppm1 encodes a large polypeptide comprising 
of two unique domains: Mt-ppm1/D1, which is membrane-anchored via six 
transmembrane segments and Mt-ppm1/D2 which is sufficient for DPM synthase 
activity (Gurcha et al., 2002; Baulard et al., 2003). Conversely, in M. smegmatis, 
these two domains are encoded by two separate ORFs arranged in an operon: 
MSMEG3860 (Domain 1, Ms-ppm2) and MSMEG3859 (Domain 2, Ms-ppm1) (Figure 
3.3) (Gurcha et al., 2002). This organisation is also found in M. leprae, M. avium and 
the related C. glutamicum (Gurcha et al., 2002; Gibson et al., 2003). Studies 
conducted using bacterial two-hybrid systems has demonstrated the interaction 
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between MSMEG3859 and MSMEG3860 (Baulard et al., 2003) While MSMEG3859 
was sufficient for PPM synthase activity, interacting with MSMEG3860 ensured the 
stability of the synthase (Gurcha et al., 2002; Baulard et al., 2003).  
Figure 3.3. Genomic organisation of the ppm1 locus in various mycobacteria and in 
Corynebacterium glutamicum. Homologous genes are indicated by similar coloured arrows 
and pseudogenes in M. leprae are indicated by arrows with white borders. While the ppm1-
encoded protein consists of two domains fused together in M. tuberculosis and M. bovis, in 
M. leprae, M. smegmatis and C. glutamicum, these two domains are encoded by two distinct 
ORFs. 
 
It was similarly observed in M. tuberculosis that a recombinant protein consisting only 
of the C-terminal domain (Mt-Ppm1/D2) was sufficient for production of PPM activity 
(Gurcha et al., 2002). However, whilst in vitro data has established that Mt-Ppm1 
(and MSMEG3859) has PPM synthase activity, there have been no genetic studies 
that determine that Mt-Ppm1 is the sole PPM generating enzyme encoded by the M. 
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tuberculosis genome. If this was the case and in light of the crucial role of PPM for 
biosynthesis of LM/LAM,  Mt-ppm1 would be expected to be an essential gene and 
thus genetic studies could only be conducted via the generation of a conditional 
knockout strain.  
 
Recently, the report of conflicting results that another membrane-associated 
glycosyltransferase, Rv3779 functions as a PPM synthase in M. tuberculosis 
(Scherman et al., 2009), and as a glycosyltransferase that uses polyprenyl-P-D-
GalNAc as a D-GalNp (or D-GalNAc) donor for transfer to 3,5-branched D-Araf 
residues of AG (Skovierová et al., 2010), has further necessitated the need to study 
the in vivo role of ppm1 by generation of a conditional mutant strain. Furthermore, a 
recently published report also describes Rv3631 (ppgS) and Rv3632 as genes 
encoding a polyprenyl-P-D-GalN synthase and a small integral membrane protein, 
respectively, analogous to Mt-Ppm1/D2 and Mt-Ppm1/D1. While PpgS is a GT-2 
family glycosyltransferase, involved in the generation of polyprenyl-phospho-N-
acetylgalactosamine (polyprenyl-P-GalNAc) from polyprenyl-P and UDP-GalNAc, it 
could function as a secondary, prospective PPM synthase. 
 
In order to confirm the in vivo function of Mt-Ppm1/D2 in the biogenesis of LM/LAM, 
we aimed to test the essentiality of PPM glycosyltransferase activity in M. smegmatis 
by using conditional expression specialised transduction essentiality test (CESTET), 
a genetic tool for determining gene essentiality in M. smegmatis. As there are no 
homologues of PpgS or Rv3779 in M. smegmatis, it also provided us with a valuable 
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surrogate to investigate the in vivo role and potential essentiality of MSMEG3859 in 
the loss of any potential functional redundancy caused by an alternative PPM 
synthase. In addition, mutant or conditional mutant strains of M. smegmatis could 
consequently be used as a host strain to test functional complementation of PPM 
synthase activity using recombinant PpgS or Rv3779. 
 
3.2 Materials and Methods 
3.2.1 Bacterial strains and growth conditions 
Liquid cultures of M. smegmatis mc2155 strain were grown in Tryptic Soy Broth 
(TSB), soybean-casein digest medium (BD Difco) supplemented with 0.05% (v/v) 
Tween-80 (Sigma-Aldrich) in a shaking incubator overnight at 37 °C. For growth on 
plates, solid media were made with TSB, soybean-casein digest medium (BD, Difco) 
with addition of 1.5% (w/v) agar. Liquid cultures of E. coli were grown in Luria-Bertani 
(LB) broth in a shaking incubator overnight at 37 °C. For growth on plates, solid 
media were made with using Luria agar (Fisher Bioreagents). The concentration of 
the antibiotics used was 50 µg/ml kanamycin for E. coli, 25 µg/ml kanamycin for M. 
smegmatis, 50 µg/ml apramycin for E. coli, 25 µg/ml apramycin for M. smegmatis and 
50 ng/ml for M. smegmatis. 
 
3.2.2 Construction of recombinant plasmids 
For producing an integrative vector containing MSMEG3859, the ORF was PCR 
amplified using Phusion High-Fidelity DNA polymerase (New England Labs) from M. 
smegmatis mc2155 (Snapper et al., 1990) genomic DNA using the primers F3859 
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and R3859, cloned downstream of the tetracycline promoter in the integrative vector 
pTIC6a vector containing a kanamycin resistance selection marker (gift from A. 
Baughn and W.R. Jacobs Jr., Albert Einstein College of Medicine, NY) and termed 
pTIC6a-MSMEG3859. For subsequent complementation/rescue experiments, the 
plasmid pMV261Apra, a derivative of pMV261 containing an apramycin resistance 
selection marker (Stover et al., 1991), was used for cloning various GTFs using 
Phusion High-Fidelity DNA polymerase (New England Labs). MSMEG3859 was 
amplified using primer pairs F3859A and R3859; the C-terminal domain of Rv2051c 
(Mt-ppm1/D2) using primer pairs F2051C and R2051C; Rv3779 using F3779 and 
R3779; Rv3631 (ppgS) using F3631 and R3631. The-PCR amplified DNA fragments 
of MSMEG3859, Mt-ppm1/D2, Rv3779 and ppgS were cloned into pMV261Apra 
using primer-incorporated restriction sites and the resultant plasmids were named 
pAKR-MSMEG3859, pAKR-Mt-ppm1/D2, pAKR-Rv3779 and pAKR-ppgS, 
respectively. Table 3.1 outlines the sequence and restriction site incorporated in 
oligonucleotide primers used in the construction of recombinant plasmids. The 
production of all oligonucleotide primers and the sequencing of generated constructs 
were performed by Eurofins MWG Operon (Ebersberg, Germany). 
 
 
 
 
 
 
Chapter 3                                                                Essentiality of PPM synthase 
79 
 
Table 3.1. Oligonucleotide primers used for PCR of various glycosyltransferases from 
M. smegmatis and M. tuberculosis. Restriction site is underlined. 
Oligonucleotide Restriction site Sequence (5’ → 3’) 
F3859  EcoRI TCGGAATTCATGAGCGTCCCCGGTGAACG 
R3859 ClaI GCTATCGATTCAGCGGACCACGCCCCTGG 
F3859A  PvuII GCGGTCAGCTGATGAGCGTCCCCG 
F2051C  MscI GCTGCTGGCCAACCACCGGCCAGC 
R2051C  HindIII ATAAGCTTCTCATTCGGTCACGTC 
F3779  MscI GATGGCCAGTGGGCCTGTGGTTCG 
R3779  HindIII ATAAGCTTCCTAGGAGTGTGTTGC 
F3631  MscI GCTCGTGGCCAATGGCCTCGAAAA 
R3631  ClaI TCGACATCGATTCATCGTGGCATC 
 
3.2.3 Generation of knockout phage for null mutant creation using specialised 
transduction 
Approximately 1 kb sequences of the upstream and downstream regions of the 
MSMEG3859-MSMEG3860 genes were PCR-amplified from M. smegmatis mc2155 
genomic DNA using the following primer pairs: RL-3859 (5‟-
TTTTTTTTCCATAGATTGGTACTCCGTGCTGGTCGAGATG-3‟) and RR-3859 (5‟-
TTTTTTTTCCATCTTTTGGCGAGGAGTTCGACGTAG-3‟). Figure 3.4 shows the 
sequential procedures involved in generation of the knockout phage. 
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Figure 3.4. Schematic representation of sequential events leading to the generation of 
the knockout plasmid. These steps lead to the generation of a recombinant phage which is 
used to replace the targeted gene by specialized transduction. Adapted from Bhatt et al., 
2009. 
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The PCR products were purified and the primer incorporated Van91I sites were 
digested with Van91I, following which the digested PCR fragments were cloned into 
Van91I-digested p0004S to generate the allelic exchange plasmid phΔMsPpm. One 
positive plasmid was PacI digested and ligated to PacI digested phAE159 DNA. The 
ligation mix was then packaged into empty λ-phage heads and transduced into E. coli 
HB101. Cells containing phasmid DNA were selected for on LB agar containing 
hygromycin at 37 °C. Packaging of phΔMsPpm into phAE159 was confirmed by PacI 
digestion.  The positive phasmids were transformed by electroporation into M. 
smegmatis at 1800V and recovered at 30 °C for ~4 hours in TSB. The recovered 
cells were then harvested and resuspended in 200 µl of MP buffer (50 mM Tris pH 
7.8, 150 mM NaCl, 10 mM MgCl2, 2 mM CaCl2). This was mixed with 200 µl of freshly 
growing M. smegmatis and 5 ml molten soft agar (50 °C) and poured on 7H9 basal 
agar plates and incubated at 30°C for 2 -3 days and allowed to form plaques. The 
plates were soaked in minimum amount of MP buffer for 5-6 hours and the solution 
containing phages was filtered and stored at 4 °C. This generated the recombinant 
phage – phΔMsPpm designed to substitute the MSMEG3859-MSMEG3860 genes 
with a hygromycin resistance marker.  
 
3.2.4 Generation of the ΔMsPpm Conditional Mutant 
The M. smegmatis conditional mutant ΔMsPpm was generated using CESTET 
(Figure 3.5) (Bhatt et al., 2005). Briefly, the integrative vector pTIC6a-MSMEG3859 
was introduced by electroporation into M. smegmatis mc2155 to generate a 
merodiploid strain named mc2155::pTIC6a-MSMEG3859 (Bhatt et al., 2005). 
Subsequently, the merodiploid strain was subjected to specialised transduction, as 
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previously described (Bardarov et al., 2002), using a temperature-sensitive, 
recombinant phage phΔMsPpm designed to substitute MSMEG3859-MSMEG3860 
with a hygromycin resistance marker. Transductants were selected at the non-
permissive temperature of 37 °C on selective plates containing 25 µg/ml kanamycin, 
100 µg/ml hygromycin B and 50 ng/ml anhydrotetracycline (ATc). After replacement 
of the gene was confirmed by Southern blot, one such transductant was termed the 
ΔMsPpm conditional mutant and was selected for further analysis. 
 
Figure 3.5. Schematic representation of CESTET. After specialised transduction using a 
phage delivery system to replace the putative essential (peg) on the bacterial chromosome 
with a chromosome marker, cells are spread onto plates containing hygromycin with or 
without anhydrotetracycline. The tetracycline promotor will induce the expression of peg in 
the presence of anhydrotetracycline leading to the growth of bacterial colonies. kan, 
kanamycin resistance cassette; hyg, hygromycin resistance cassette; Hyg, hygromycin; 
Ptetracycline, inducible tetracycline promoter. The interrupted arc represents the integrative 
vector, the solid arc represents the mc2155 chromosome, and the dotted strand represents 
phage DNA. Adapted from Bhatt et al., 2005. 
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3.2.5 Southern blotting 
Genomic DNA was extracted from wild-type M. smegmatis and the ΔMsPpm 
conditional mutant strains using the method described in Section 6.9 and digested 
with SmaI. The agarose gel was depurinated in 0.25 M HCl for 10 min, followed by 
denaturation (1.5 M NaCl, 0.5 M NaOH) for 10 -15 minutes and finally neutralised for 
15-20 minutes (0.5 M Tris-HCl pH 7.2, 1 M NaCl ). The DNA on the gel was then 
transferred onto a nylon membrane (Nylon Membrane, positively charged, No-
11209299001, Roche) by capillary transfer with 20× SSC (3 M NaCl, 0.3 M sodium 
citrate, pH 7.0), overnight. DNA was fixed to the membrane by UV cross-linking. After 
cross-linking, the membrane was rinsed with distilled water and used for 
hybridisation, labelling and detection. The procedure was performed as described in 
DIG High Prime DNA Labelling and Detection Starter Kit II (cat no – 11585614910, 
Roche). This kit uses digoxigenin, a steroid to label DNA probes by random priming. 
The hybridised probes are then immunodetected by anti-digoxigenin-AP (Fab 
fragments), which are visualised by chemiluminescence. The expected gene sizes 
were 1.7 kb and 3.3 kb for the wild-type M. smegmatis and 7.4 kb for the ΔMsPpm 
conditional mutant. 
 
3.2.6 Conditional depletion of ΔMsPpm conditional mutant 
The ΔMsPpm conditional mutant was grown in Tryptic Soy Broth (TSB; BD, Difco) 
containing 0.05% Tween 80, 25 µg/ml kanamycin, 100 µg/ml hygromycin B and 50 
ng/ml ATc. Subsequently, the ΔMsPpm conditional mutant was passaged twice in 
medium without ATc. To visualise the effects of the conditional depletion of 
MSMEG3859 in ΔMsPpm on polar lipids and lipoglycans, the strains were grown to 
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OD 0.8, labelled with 10 µCi/ml glucose D-[14C(U)] (specific activity 250–360 mCi 
(9.25–13.3 GBq)/mmol; Perkin Elmer) and incubated at 37 °C for 4 h. 
 
3.2.7 Extraction of polar lipids 
Polar and apolar lipids were extracted as described in Section 6.10. Incorporation of 
glucose D-[14C(U)] was quantified by liquid scintillation counting using 5% of the lipid 
fractions in 5 ml EcoScint A (National Diagnostics). The polar lipid extracts were 
examined by two dimensional thin-layer chromatography (2D-TLC) on aluminium-
backed plates of silica gel 60 F254 (Merck 5554) by spotting equal counts of polar 
lipid extracts (50,000 cpm), which were then developed using solvent system E for 
polar lipids: chloroform/methanol/water (60:30:6, v/v/v) in the first direction and 
choloroform/acetate/methanol/water (40:25:3:6, v/v/v/v) in the second direction. Polar 
lipids were visualised by 48 h exposure on X-ray films by autoradiography (Kodak 
Biomax MR film). 
 
3.2.8 Extraction and purification of lipoglycans 
Lipoglycans were extracted as described previously (Ludwiczak et al., 2001). Briefly, 
dried cells from a 10 ml volume culture were re-suspended in deionised water. 
Ethanol extraction was carried out by mixing 50% C2H5OH to the cell suspension and 
reﬂuxing at 68 °C, for 6 h followed by centrifugation and recovery of the supernatant. 
This C2H5OH/H2O extraction was repeated five times and the combined supernatants 
were dried. The dried supernatant was subjected to hot phenol-H2O treatment at 65 
°C. The aqueous phase containing the crude lipoglycan fraction was dialysed against 
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deionised water, dried and the incorporation of glucose D-[14C(U)] was quantified by 
liquid scintillation counting using 5 % of the lipoglycan fractions in 5 ml EcoScint A 
(National Diagnostics). Equal counts (50,000 cpm) were loaded on a 15% SDS-
PAGE gel and separated by electrophoresis (described in Section 6.14). Lipoglycans 
were visualised by 48 h exposure on x-ray films by autoradiography (Kodak Biomax 
MR film). 
 
3.2.9 PPM synthase assay 
Membranes were prepared as described previously (Besra et al., 1997). Briefly, cells 
were grown to mid-log phase, harvested, washed with PBS and stored at –20 °C. 
Cells were first washed and resuspended in 30 ml buffer A containing 50 mM MOPS 
(adjusted to pH 7.9 with KOH), 5 mM β-mercaptoethanol and 10 mM aqueous MgCl2 
at 4 °C and subjected to sonication for a total time of 10 min using 60 s pulses and 
90 s cooling intervals. The preparations were centrifuged at 27000×g for 25 min at 4 
°C and the membranes were obtained by further centrifugation of the supernatant at 
100,000×g for 1 h at 4 °C. The membranes were resuspended in 1 ml of buffer A and 
the concentration was determined using the BCA Protein Assay Reagent Kit (Thermo 
Scientific). Reaction mixtures for assessing [14C]Man incorporation consisted of 6.25 
µCi GDP[Man-14C(U)] (262 mCi/mmol; Perkin Elmer), 100 µM ATP, 10 mM aqueous 
MgCl2, 100 µM dithiothreitol, 20 mM NaF(aq) and membrane preparations 
corresponding to 50–400 µg protein in a final volume of 100 µl. Decaprenyl 
monophosphate was added to the reaction mixtures at a final concentration of 125 
µM. The reaction mixtures were then incubated at 37 °C for 30 min. The enzymic 
reactions were terminated by the addition CHCl3/CH3OH/0.8 M aqueous NaOH 
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(10:10:3 by vol.) (6 ml/100 µl) followed by further incubation at 55°C for 20 min. The 
mixtures were then allowed to cool; 2.625 ml of CHCl3 and 1.125 ml of water were 
added. The mixture was vortexed and centrifuged and the upper aqueous phase 
discarded. The organic phase was washed three times with 2 ml of 
CHCl3:CH3OH:H2O (3:47:48 by vol.), dried to yield an organic fraction containing 
PPMs. These were dried in a scintillation vial before scintillation counting using 5 ml 
of EcoScint A (National Diagnostics) (Gurcha et al., 2002). 
 
3.3 Results and Discussion  
3.3.1 Confirming the essentiality of MSMEG3859 in M. smegmatis 
Previous studies have established the role of Mt-ppm1 in the biosynthesis of LM and 
LAM, the presence of which are vital for the survival of M. tuberculosis (Gurcha et al., 
2002). This evidence indicates that it is an essential gene. We decided to test this 
hypothesis in M. smegmatis using the homologue. A knockout phage phΔMsPpm 
designed to replace MSMEG3859-MSMEG3860 in M. smegmatis with a hygromycin 
resistance cassette was constructed. However, due to the failure to yield any 
transductants, we were unsuccessful in generating a null mutant. In contrast, we 
were able to produce a MSMEG3859-MSMEG3860 null mutant by transducing a 
merodiploid strain containing a second, inducible copy of MSMEG3859-MSMEG3860 
by CESTET (Conditional Expression Specialised Transduction Essentiality Test) 
(Bhatt et al., 2005); this led to the possibility that either one or both genes are 
essential in M. smegmatis. However, as studies conducted in vitro have 
demonstrated that MSMEG3859 is sufficient for the enzymatic generation of PPM, it 
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is more likely that the PPM synthase-encoding MSMEG3859, but not the membrane 
segment-encoding MSMEG3860, was an essential gene. To clarify this, CESTET 
was again employed to test the essentiality of MSMEG3859 in M. smegmatis. First, 
we constructed a merodiploid strain by introducing a second copy of MSMEG3859 
cloned in pTIC6a, an integrative plasmid driving expression via a tetracycline 
inducible promoter (Ehrt et al., 2005).  
 
The addition of anhydrotetracycline (ATc) to the growth medium could induce 
expression of this recombinant copy of MSMEG3859. After transduction with the 
knockout phage phΔMsPpm, we were able to generate deletion mutants only when 
transductants were selected on plates containing hygromycin and ATc, leading to the 
validation that MSMEG3859 was essential in M. smegmatis. We selected one such 
conditional mutant, which was named ΔMsPpm and used this strain for further 
analysis. Subsequent passages of the ΔMsPpm mutant in medium without the 
inducer ATc led to the loss of cell viability demonstrating that expression of the 
pTIC6a-driven copy of MSMEG3859 was necessary for cell growth, confirming the 
essentiality of MSMEG3859 (Figure 3.6). 
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Figure 3.6. Essentiality of MSMEG3859 in M. smegmatis mc2155. Growth of the ΔMsPpm 
conditional mutant on Tryptic Soy Agar in the presence or absence of the inducer 
anhydrotetracycline (ATc). 10 µl of 10-fold serial dilutions of cultures were spotted on the 
agar plates and incubated for 3 days at 37 °C. 
 
3.3.2 Loss of MSMEG3859 leads to an alteration in PIM profile and cessation 
of LM biosynthesis 
As previously mentioned in Section 3.1.2, Ac1/Ac2PIM4 is at a key branch point for 
the biosynthesis of higher PIMs (Ac1/Ac2PIM6) and LM/LAM. Using the conditional 
ΔMsPpm mutant, we could determine whether losing the PPM activity of 
MSMEG3859-encoded could lead to a change in the biosynthesis of higher PIMs and 
LM/LAM. The mutant was grown for 36 hours in media in the presence, or absence, 
of ATc and labelled with [14C]-glucose. The cells were then subjected to lipid 
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extractions. In the cultures grown in ATc-containing media, all of the PIM 
intermediates were present (Figure 3.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. 2D-TLC autoradiograph of [14C]-labelled polar lipids from the ΔMsPpm 
conditional mutant. Cultures were grown and labelled in Tryptic Soy Broth in the presence 
or the absence of anhydrotetracycline (ATc). Equal counts of polar lipid extracts (50,000 
cpm) were applied to TLC plates. Solvent system E for polar lipids: CHCl3/CH3OH/H2O 
(60:30:6, v/v/v) in the first direction and CHCl3:CH3OOH: CH3OH:H2O (40:25:3:6, v/v/v/v) in 
the second direction. Polar lipids were visualised by 48 h exposure on x-ray films by 
autoradiography (Kodak Biomax MR film). PIM intermediates are shown by arrows (x = 3–5) 
and the dotted circle indicates the position of the higher PIMs on the TLC plates. 
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In contrast, cultures of the conditional mutant grown in media without ATc displayed 
similar amounts of PI accompanied by decreasing levels of Ac1/Ac2PIM6 (Figure 3.7). 
The loss of Ac1/Ac2PIM6 and accumulation of PIMx precursors suggested that 
MSMEG3859 is required for the synthesis of higher order PIMs, particularly 
Ac1/Ac2PIM6.  
 
Conditional depletion of PPM synthase activity in the ΔMsPpm mutant should also 
affect the biosynthesis of lipoglycans. Cultures that were grown in media without ATc 
did show diminished levels of [14C]LM (Figure 3.8). However, we did not detect any 
major differences in [14C]LAM levels (Figure 3.8).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Lipoglycan profile of the ΔMsPpm conditional mutant. Equal counts (50,000 
cpm) of [14C]-labelled lipoglycan fractions were separated on 15% SDS-PAGE gel from 
cultures of the ΔMsPpm conditional mutant with or without anhydrotetracycline (ATc). 
Lipoglycans were visualised by 48 h exposure on x-ray films by autoradiography (Kodak 
Biomax MR film). 
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This observation can be explained by results reported by Besra et al., where dual 
[14C]/[3H] dual labelling experiments have shown that residual LM can lead to the 
production of LAM (Besra et al., 1997). The loss of [14C]LM but presence of [14C]LAM 
in the depleted cultures could be explained by residual LM molecules utilising 
synthesised endogenous PPM generated prior to conditional depletion for the 
extension of form [14C]LAM. Therefore, it is likely that the [14C]LAM we observed in 
the depleted cells was probably generated from residual unlabelled LM, rather than 
newly synthesised LM. These data suggest that MSMEG3859, which encodes the 
equivalent of M. tuberculosis Ppm1/D2, is solely responsible for the PPM synthase 
activity required for the generation of higher order PIMs and LM/LAM. 
 
3.3.3 Effects of loss of MSMEG3859 on membrane-associated PPM synthase 
activity 
Membrane preparations from cultures of the ΔMsPpm mutant, grown in the presence 
and in the absence of ATc, were used to assay membrane-associated PPM synthase 
activity. A PPM synthase assay was used to analyse PPM activity in the membranes 
using GDP-[14C] Man and polyprenol phosphate as substrate. This assay was used 
to assess the effects of depletion of MSMEG3859 function on the ability of the 
membrane preparations to catalyse the formation of PPM (C50-P-Man) donors via the 
incorporation of radioactive mannose into polyprenol substrate through pooled 
organic extracts containing PPMs (Gurcha et al., 2002). While membrane 
preparations from cultures grown in the presence of ATc were able to catalyse the 
incorporation of [14C] Man into polyprenols, those from cultures grown in the absence 
of ATc displayed poor PPM synthase activity (Figure 3.9). Thus, the PPM synthase 
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activity from MSMEG3859 encoding membrane extracts was significantly increased 
compared with membrane extracts with loss of MSMEG3859. This co-relation 
between depleted MSMEG3859 function and low PPM synthase activity confirmed 
that MSMEG3859 was the key synthase required to catalyse the production of PPM 
donors in M. smegmatis. 
 
Figure 3.9. PPM synthase activity in membranes of the ΔMsPpm conditional mutant. 
Graph shows the transfer of [14C]-mannose from GDP[Man-14C(U)] (262 mCi/mmol; Perkin 
Elmer) to polyprenol-phosphate in membrane extracts prepared from cultures grown with or 
without anhydrotetracycline (ATc). 
 
3.3.4 Potential ability of alternative M. tuberculosis PPM synthases to rescue 
viability and restore wild-type phenotype in the ΔMsPpm mutant 
Recent studies have identified two other membrane-associated glycosyltransferases, 
Rv3779 and Rv3631 (PpgS) in M. tuberculosis which are responsible for the transfer 
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of the GalN substrate for the modification of AG (Skovierová et al., 2010). However, 
they have also been suggested to have putative roles as PPM synthases in M. 
tuberculosis (Skovierová et al., 2010). As there are no homologues of Rv3779 or 
Rv3631 (PpgS) present in M. smegmatis, the ΔMsPpm conditional mutant thus 
offered us an opportunity to assess the potential roles of Rv3779 and PpgS as 
alternative PPM synthases. Each gene could be functionally analysed in vivo by 
testing the ability of the ΔMsPpm conditional mutant transformed with a plasmid-
borne copy of either Rv3779 or ppgS to restore PPM synthase activity and thereby 
rescue Ac1/Ac2PIM6 biosynthesis when cultured in medium devoid of ATc. As 
expected, Ac1/Ac2PIM6 biosynthesis was not affected in non-ATc cultures of 
ΔMsPpm containing plasmid clones of either MSMEG3859 (Figure 3.10). We then 
tested the ability of the M. tuberculosis equivalent, Mt-ppm1/D2 to rescue the loss of 
MSMEG3859 function in the same manner and found Ac1/Ac2PIM6 levels unaffected 
in the recombinant strains (Figure 3.10) thus demonstrating that Mt-ppm1/D2 was 
functional in M. smegmatis. However, Rv3779 was unable to rescue Ac1/Ac2PIM6 
biosynthesis in the conditional mutant when grown in the absence of ATc, leading to 
a loss of Ac1/Ac2PIM6 and a noticeable accumulation of intermediate Ac1/Ac2PIMxs 
(Figure 3.10). While Rv3779 was shown to have PPM synthase activity in vitro 
(Scherman et al., 2009), it surprisingly failed to substitute for loss of MSMEG3859 in 
the conditional ΔMsPpm mutant. Thus, in contrast to its in vitro activity, it is unlikely 
that Rv3779 functions in vivo as a PPM synthase. However, the predominant role of 
Rv3779 in M. tuberculosis appears to be the utilisation of polyprenyl-P-D-GalNAc as 
a donor for the biosynthesis of galactosamine-modified AG (Skovierová et al., 2010). 
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Figure 3.10. Complementation of the ΔMsPpm conditional mutant. 2D-TLC analysis of 
[14C]-labelled polar lipids from the ΔMsPpm conditional mutant complemented with (A) pAKR-
MSMEG3859 (B) pAKR-Mt-ppm1/D2 (C) pAKR-Rv3779 (D) pAKR-ppgS. System E for polar 
lipids: CHCl3/CH3OH/H2O (60:30:6, v/v/v) in the first direction and CHCl3:CH3OOH: 
CH3OH:H2O (40:25:3:6, v/v/v/v) in the second direction. Polar lipids were visualised by 48 h 
exposure on x-ray films by autoradiography (Kodak Biomax MR film). PIM intermediates are 
shown by arrows (x = 3–5) and the dotted circle indicates the position of the higher PIMs on 
the TLC plates. 
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As mentioned above, while PpgS is involved in the generation of polyprenyl-
phospho-N-acetylgalactosamine (polyprenyl-P-GalNAc) from polyprenyl-P and UDP-
GalNAc, it could be envisaged as a secondary, potential PPM synthase. Its syntenic 
association with the small integral membrane protein Rv3662 is similar to 
MSMEG3859 and its associated transmembrane protein MSMEG3860, and Mt-
Ppm1/D2-Mt-Ppm1/D1, which is fused as one polypeptide. However, ppgS was also 
unable to compensate for the loss of MSMEG3859 in the conditional mutant (Figure 
3.10), and thus is unlikely to function as a PPM synthase in vivo. Therefore, these 
results demonstrate that both Rv3779 and PpgS do not have a role as a PPM 
synthase. 
 
3.4 Conclusion 
Several studies have displayed the importance of LAM as a key factor in TB 
pathogenesis. The initial steps in the biosynthesis of PIMs utilise an intracellular 
nucleotide-derived mannose donor called GDP-Manp, whereas a polyprenyl-
phosphate-based mannosyl donor is required the synthesis of higher PIMs, LM and 
LAM in the periplasmic side of the bacterium. While the first polyprenyl-phosphate-
based mannose donor to be identified was C50-decaprenol-phospho-mannose (C50-
P-Manp, PPM) in M. tuberculosis, an additional alkali-stable PPM donor, C35-
octahydrohepta-prenyl-phosphate-mannose (C35-P-Manp) was identified in M. 
smegmatis (Takayama and Goldman, 1970; Wolucka and de Hoffmann, 1998). 
Previous studies have identified a PPM synthase in M. tuberculosis encoded by the 
two-domain gene Mt-ppm1 and two separate proteins encoded by neighbouring 
genes in M. smegmatis (Gurcha et al., 2002). Mt-ppm1 was probably formed by the 
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consequence of a genetic fusion between ancestral genes. Since ppm1 genes are 
conserved across mycobacteria, especially M. leprae which possess a highly 
reduced genome (Cole et al., 2001), this leads to the suggestion that PPM synthase 
is an essential enzyme in mycobacteria.  
 
The ability to generate an MSMEG3859-MSMEG3860 double mutant in a 
MSMEG3859 merodiploid strain indicated that while the PPM synthase-encoding 
MSMEG3859 was essential, MSMEG3860 (which encodes a six transmembrane 
section-containing membrane-anchored protein) was not essential. This correlated 
with earlier reports that MSMEG3859 was sufficient for PPM synthase activity 
(Gurcha et al., 2002; Baulard et al., 2003). In addition to this, both Rv3779 and PpgS 
were unable to compensate for the loss of MSMEG_3859 in the ΔMsPpm conditional 
mutant, therefore proving that they do not have a role as a PPM synthase. 
 
The results from this Chapter indicate that ppm1 is the gene encoding the sole PPM 
synthase in M. tuberculosis that is capable of generating the mannose donor for the 
biosynthesis of higher order PIMs and LM/LAM. Together, the data obtained from the 
depletion experiments with the conditional mutant highlight the potential of the 
MSMEG3859-encoded PPM synthase as a potential drug target that affects not only 
viability, but also the biosynthesis of an immunomodulatory mycobacterial lipoglycan.  
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4 Deletion of the serine/threonine 
protein kinase H alters phthiocerol 
dimycocerosate synthesis 
in Mycobacterium tuberculosis 
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4.1 Introduction 
4.1.1 Biosynthesis of phthiocerol dimycocerosates (PDIMs) 
As explained above in Section 1.6.6, phthiocerol dimycocerosates (PDIMs) are a 
family of surface-exposed polyketide lipids which are found in the outer membrane 
segment of M. tuberculosis.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Structure of PDIMs. The long chain β-diol backbone known as phthiocerols is 
esterified by polymethyl-branched fatty acids (mycocerosic  acids). R1 is CH2-CH3 for 
phthiocerol series A and C or CH3 for phthiocerol series B; R
2 is OCH3 for the phthiocerol 
family or is O for the phthiodiolone family (series C). 
 
PDIMs are composed of a mixture of long-chain β-diols (C33–C41) known as 
phthiocerols that are esterified by two long-chain polymethyl-branched fatty acids 
called mycocerosic acids (Figure 4.1) (Minnikin et al., 2002) and have been shown to 
possess immunological activity in host macrophages during infection (Rousseau et 
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al., 2004; Astarie-Dequeker et al., 2009). PDIM A/B is the phthiocerol 
dimycocerosate variant with a methoxy group at the terminus of the β-diols, whereas 
PDIM C is its structural variant that contains a keto group instead. 
 
The biosynthetic pathway of PDIMs has been studied in detail. Biosynthesis is 
initiated by fatty acyl-AMP ligases called FadD26 and FadD28, which are involved in 
the activation and transfer of C12–C18 fatty acids for production of the phthiocerol 
moiety and mycocerosic acids, respectively  (Figure 4.2) (Trivedi et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Pathway of phthiocerol dimycocerosates (PDIMs) biosynthesis. FadD26 and 
FadD28 activate and transfer fatty acids to PpsA-E and Mas, respectively. PpsA-E 
synthesise the phthiocerol backbone, which is then released by TesA. In parallel, Mas 
protein synthesises mycocerosic acids, which are transferred to the phthiocerol backbone by 
PapA5. MmpL7 and DrrC are responsible for transporting of PDIM to the cell wall. Mas, 
mycocerosic acid synthase; Pps, phthiocerol synthase. 
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The activated fatty acids are transported to the type I polyketide synthases (PKSs), 
PpsA-PpsE, which are responsible for the elongation of straight-chain fatty acids until 
the synthesis of the final phthiocerol backbone is complete (Azad, 1997; Trivedi et 
al., 2005). In parallel, activated fatty acids are transferred to an iterative type PKS, 
the Mas protein, which synthesises mycocerosic acids through sequential additions 
of methyl malonyl CoA (Azad et al., 1996; Trivedi et al., 2005). PapA5, an 
acyltransferase protein, catalyses the direct transfer of mycocerosic acids to the β-
diol backbone of the phthiocerol to complete the final esterification step (Onwueme et 
al., 2004; Trivedi et al., 2005). The elongated phthiocerol moiety is released from 
PpsE through interaction with the type II thioesterase TesA (Alibaud et al., 2011). 
The newly synthesised PDIMs are then transported to the cell wall by either MmpL7 
or DrrABC (Camacho et al., 1999; Cox et al., 1999). 
 
4.1.2 Serine/threonine protein kinase H (PknH) 
Although there is a good understanding of the biosynthesis of PDIMs, there is limited 
knowledge regarding their regulation. Protein phosphorylation is the central 
mechanism by which extracellular environmental stimuli are converted into cellular 
responses. These mechanisms can be enabled by protein kinases that allow the 
bacterium to adapt its cellular response to survive in hostile environments. Protein 
kinases are categorised into two families: the sensor histidine kinases, part the two-
component regulatory systems, which autophosphorylate a conserved histidine 
residue (Stock et al., 1989) and the serine/threonine protein kinases (STPK)s, which 
phosphorylate serine and threonine residues (Hanks et al., 1988). Recently, 
serine/threonine phosphorylation has been found to play a critical regulatory role in 
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signal transduction pathways in M. tuberculosis. The genome of M. tuberculosis 
possesses 11 different STPKs which have been implicated in the regulation of 
pathogenesis, cell division and cell-wall biosynthesis (Cole et al., 1998; Av-Gay and 
Everett, 2000; Chao et al., 2010). Previous studies have identified two STPKs, PknB 
and PknD, that are associated with PDIM biosynthesis. While PknB was shown to 
phosphorylate threonine residues in PapA5 (Gupta et al., 2009), PknD may be 
involved in the phosphorylation of MmpL7 (Pérez et al., 2006). The experimental 
evidence from these studies proposes that STPKs are involved in the regulation of 
PDIM production. 
 
The M. tuberculosis PknH kinase has previously been shown to phosphorylate 
enzymes involved in the synthesis of the cell wall. Previous in vitro kinase assays 
provided experimental evidence that PknH directly phosphorylates the endogenous 
EmbR protein through the recognition of a forkhead-associated domain (FHA), which 
represented the first example of a protein substrate altered by a STPK in M. 
tuberculosis (Molle et al., 2003). The FHA domain is capable of facilitating protein-
protein interactions through recognition of phosphothreonine (Durocher and Jackson, 
2002). As EmbR is the transcriptional regulator of the embCAB operon, encoding 
arabinosyltransferases which are involved in the synthesis of the arabinan domain of 
AG and LAM, this interaction may play a role in the various production of cell-wall 
components (Molle et al., 2003; Sharma et al., 2006; Zheng et al., 2007). The 
interaction of PknH with EmbR has also been found to significantly alter EMB 
resistance by regulating transcription levels of the embAB genes which are the 
cellular target of EMB (Sharma et al., 2006). Furthermore, in vivo studies in which 
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PknH was overexpressed in M. smegmatis resulted in a high LAM/LM ratio, which is 
critical in the virulence of mycobacteria (Sharma et al., 2006). PknH is also involved 
in the phosphorylation of DacB1, a sporulation-specific penicillin-binding protein, 
which is involved in cell-wall biosynthesis (Zheng et al., 2007).  
 
Recent studies have investigated the physiological and virulence properties of PknH 
kinase in M. tuberculosis (Papavinasasundaram et al., 2005). In a study by 
Papavinasasundaram et al., it was demonstrated that the deletion of PknH leads to 
increased resistance to acidified nitrite stress in vitro, suggesting this protein 
regulates the in vivo growth of M. tuberculosis in response to nitric oxide 
(Papavinasasundaram et al., 2005). Moreover, it was shown that the ΔpknH mutant 
leads to improved survival and replication in a BALB/c mouse model of infection, 
indicating that PknH is needed to facilitate adaptation to the host environment to 
regulate the in vivo growth of M. tuberculosis (Papavinasasundaram et al., 2005). 
Recently, it was also identified that PknH is associated with the M. tuberculosis 
dormancy regulon through phosphorylation of the control enzyme DosR (Chao et al., 
2010). Together, these results indicate that PknH plays a central role in regulating 
the growth of M. tuberculosis by controlling the synthesis of cell-wall components 
and/or transport. In this study, we investigated how PknH affects the biosynthesis of 
PDIM and the ratio of LAM to LM. To examine this, a pknH deletion mutant strain 
generated in the laboratory of our collaborator was used to carry out a detailed cell 
wall lipid analysis to observe PDIM production and to characterise LAM and LM 
levels. Dr. Anaximandro Gómez-Velasco and Prof. Yossef Av-Gay (Univerisity of 
British Columbia) used techniques including radiolabelling, mass spectrometry 
Chapter 4                                                                Deletion of protein kinase H 
103 
 
(lipidomics) and immunostaining analyses to show PDIM biosynthesis is affected by 
knocking out the pknH gene. The work described in this chapter reflects the lipid 
analysis and the lipoglycan characterisation done by me as a part of this 
collaboration.  
 
4.2 Materials and methods 
4.2.1 Bacterial strains and growth conditions 
M. tuberculosis H37Rv, ΔpknH and ΔpknH : : pknH strains were used in this study 
(Papavinasasundaram et al., 2005). Glycerol stocks were used to initiate starter 
cultures in 10 ml 7H9 Middlebrook (BD, Difco) broth supplemented with 10 % (v/v) 
oleic acid/albumin/dextrose/catalase (OADC), and 0.05 % (v/v) Tween-80 (Sigma-
Aldrich) at 37 °C. Actively growing bacterial cells were used to start 500 ml cultures 
for rolling conditions (850 cm3 roller bottles; Greiner Bio-one, catalogue no. 680060, 
1.25 rpm) and were incubated at 37 °C. 7H11 agar medium (BD, Difco) was prepared 
according to the manufacturer‟s instructions and was supplemented with 10 % (v/v) 
OADC (BD, Difco). Antibiotics were supplemented 25 µg/ml kanamycin and 50 µg/ml 
hygromycin as required: 
 
4.2.2 Extraction of polar lipids and apolar lipids 
For cell-wall lipid analysis, mycobacterial strains were grown at early exponential 
phase (OD600 ~1). Polar and apolar lipids were extracted using the method described 
in Section 6.10. Each lipid extract (100 µg) was loaded onto aluminium-backed plates 
of silica gel 60 F254 (Merck 5554) and the lipids were separated by 2D-TLC using 
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solvent systems A–E (Dobson, 1985). To visualise PDIMs, lipids were separated 
using the system A solvent system: thrice with petroleum ether (60-80 °C): EtOAc 
(98:2, v/v) in the first direction and once with petroleum ether (60-80 °C)/ acetone 
(98:2, v/v) in the second direction. The TLC plates were developed by staining with 5 
% (w/v) ethanolic phosphomolybdic acid for detecting all lipids or α-naphthol-sulfuric 
acid for detecting carbohydrate containing lipids, followed by charring at 100 °C.  
 
4.2.3 Extraction, purification and characterisation of lipoglycans 
Lipoglycans (LAM and LM) were extracted as described previously (Ludwiczak et al., 
2001). Briefly, dried cells from a 10 ml volume culture were re-suspended in 
deionised water. Ethanol extraction was carried out by mixing 50% EtOH to the cell 
suspension and reﬂuxing at 68 °C for 6 h, followed by centrifugation and recovery of 
the supernatant. This EtOH/H2O extraction was repeated five times and the 
combined supernatants were dried. The dried supernatant was subjected to hot 
phenol-H2O treatment at 65 °C (Ludwiczak et al., 2001). The aqueous phase 
containing the crude lipoglycan fraction was dialysed against deionised water and 
dried. To determine the LAM/LM ratio, equal amounts of the extracted lipoglycans 
(10 μg/ml) were loaded into 15% SDS-PAGE gel, separated by electrophoresis 
(described in Section 6.14) and visualised using Pro-Q emerald glycoprotein stain 
(Invitrogen) as explained in the manufacturer‟s handbook. The LAM/LM ratio was 
calculated by densitometric analysis. Glycoside composition was determined as 
described previously (Tatituri, 2007). Lipoglycan samples were per-O-methylated and 
then hydrolysed using 250 μl of 2 M trifluoroacetic acid at 120 ºC for 2 h, reduced 
using 100 μl of a 10 mg/ml solution of NaB2D4 (1 M aqueous NH4OH /EtOH, 1:1, v/v), 
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and per-O-acetylated by treating with 100 μl of acetic anhydride for 1 h at 110 ºC. 
After cooling, 100 μl of toluene was added to the reaction mixture and the volatiles 
removed under compressed N2. The resulting alditol acetates were partitioned 
between 2 ml H2O and 2 ml CHCl3 and the organic phase dried under compressed 
N2. The alditol acetates were examined by gas chromatography (GC) using a 
Thermoquest Trace GC 2000 equipped with flame ionisation detector. Parameters, 
conditions and analysis were performed as described previously (Tatituri et al., 
2007). 
 
For radiolabelling experiments [1-14C]-propionate 3.7×1010 Bq ml−1 [specific activity 
54 mCi mmol−1 (1.998 GBq mmol−1); American Radiolabeled Chemicals] was added 
to 10 ml mycobacterial cultures at 37 °C at different time points: 12 and 24 h, 5 and 
10 days. PDIMs were extracted and activity was measured in a scintillation counter 
(Beckman). PDIMs were purified as above using preparative TLC. Equal radioactive 
counts were loaded onto 2D-TLC and autoradiograms were visualised using a 
Phosphorimager SI (Molecular Dynamics). For lipid quantification, spots were 
scraped from TLC plates and subjected to scintillation counting. For statistical 
analysis three independent biological replicates were used. 
 
4.2.4 Fourier transform ion cyclotron resonance (FT-ICR) MS analysis 
Total lipids were extracted using the Bligh–Dyer method (Bligh and Dyer, 1959) from 
mycobacterial strains that were grown in the conditions described in Section 4.2.1. 
Tween-80, used as a supplement in the culture, was removed to avoid interference 
with the results by resuspending cells extracts in a hexane/water mixture (50 : 50, v/v), 
Chapter 4                                                                Deletion of protein kinase H 
106 
 
mixed thoroughly and centrifuged at 3500 × g for 5 min (Jain et al., 2007). The 
organic layer was extracted with water five times. For lipidomic analysis, total lipids 
were resuspended in a chloroform/methanol mixture (2 : 1, v/v) and introduced into an 
Apex-Oe 12-Tesla Hybrid quadrupole-FT-ICR machine (Bruker Daltonics), which was 
equipped with an Apollo electrospray ionization (ESI) ion source. Samples were 
infused into the MS instrument at a flow rate of 2 µl/min and were ionised with ESI. 
Mass spectra were acquired within a mass to charge (m/z) ratio range of 250–300 in 
either positive or negative mode, with broadband detection and using a data 
acquisition size of 1024 kilobytes per second. Each spectrum was accumulated from 
100 scans. Total abundance of lipid species was calculated by summing the peak 
intensities as measured by FT-ICR, as reported previously by Jain et al. (Jain et al., 
2007). 
 
4.2.5 Production of single-chain, fragment-variable (scFv) antibodies 
Purified PDIMs were kindly provided by Dr Jean-Marc Reyrat (INSERM-UMR, 
France). ScFv antibodies against purified PDIMs were selected as described 
previously (Bach et al., 2001). Briefly, 1.7 mg purified PDIMs was dissolved in 100 µl 
chloroform, followed by the addition of 100 µl 0.1 M 2-(N-morpholino) ethanesulfonic 
acid, (pH 4.5). The sample was sonicated, mixed with 30 µl 10 nM stock solution of 
hydrazine and incubated at 65 °C for 10 min. After cooling down the reaction to room 
temperature, the mixture was conjugated to 4 mg BSA using 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride (Pierce), according to the 
manufacturer‟s instructions. The Tomlinson I scFv antibodies library was kindly 
supplied by Geneservice, Cambridge, UK. The scFv antibodies were screened 
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according to the instructions supplied with the library. PDIMs coupled to BSA were 
used as antigens for screening. Selected antibodies were subcloned into pMAL-C5X 
(New England Biolabs) and generated as recombinant proteins fused to a maltose-
binding protein (MBP) as described previously (Bach et al., 2001). 
 
4.2.6 Immunostaining and fluorescence microscopy 
Bacteria were labelled with rhodamine (10 mg/ml) for 1 h at 37 °C with gentle 
rocking. Labelled bacteria were washed three times with PBS and three times with 
double-distilled water and were immobilised on coverslips by flaming. Coverslips 
containing bacterial cells were incubated with scFv antibodies at room temperature 
for 30 min. Unbound antibodies were washed away with PBS for 10 min and this step 
was repeated three times. Coverslips were further incubated with an anti-MBP 
antibody (1 : 1000 dilution) mixed with goat FITC-conjugated anti-mouse IgG 
secondary antibody (1 : 1000 dilution) at room temperature for 20 min. Coverslips 
were washed three times again with PBS for 10 min and mounted on glass slides 
containing FluorSave (Calbiochem). Fluorescence microscopy was used to analyse 
samples as described previously by Sendide et al. (Sendide et al., 2004). 
 
4.2.7 Isobaric tags for relative and absolute quantitation (iTRAQ) analysis 
The iTRAQ (Isobaric Tags for Related and Absolute Quantitation) analysis was 
performed as previously described (Chao et al., 2010). Strains were grown in rolling 
cultures, harvested, washed and treated with 3 mM NaNO2. Total proteins were 
extracted, digested with trypsin at 37 °C overnight and then labelled with iTRAQ 
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reagents. The labelled peptides were then separated using a strong cation exchange 
column called Polysulfoethyl A [100×4.6 mm, 5 µM, 300 Å (30 nm); Poly LC, 
Columbia, MD] in the first dimension. Initially, the column was allowed to equilibrate 
in buffer A [10 mM KH2PO4, pH 2.7 and 25 % acetonitrile (ACN)] for 20 min and then 
a gradient was applied for 30 min in 0–35 % buffer B (10 mM KH2PO4, pH 2.7, 25 % 
ACN, 0.5 M KCl). The flow rate was fixed at 0.5 ml/min. LC-MS/MS analysis was 
performed to analyse tagged peptides were by using an integrated Famos 
autosampler, Switchos II switching pump and Ultimate micropump system (LC 
Packings, Amsterdam) with a hybrid Quadrupole-time of flight (TOF) LC-MS/MS 
mass spectrometer (QStar Pulsar i), equipped with a nanoelectrospray ionization 
source (Proxeon, Odense, Denmark) and fitted with 10 µm fused-silica emitter tip 
(New Objective, Woburn, MA). The second dimensional chromatographic separation 
was conducted using a 75 µm×15 cm C18 PepMap Nano LC column [3 µm, 100 Å 
(10 nm); LC Packings, Amsterdam] and a 300 µM×5 mm C18 PepMap 2 Guard 
column [5 µm, 100 Å (10 nm); LC Packings, Amsterdam] prior to switching inline with 
the column and the MS. The mobile phase (solvent A) comprised of water/ACN 
(98: 2, v:v) with 0.05 % formic acid for sample injection and equilibration on the guard 
column at a flow rate of 100 µl/min. The tapping column was switched inline to 
producing a linear gradient by mixing it with solvent B, which was made up of 
ACN/water (98: 2, v/v) with 0.05 % formic acid, and the flow rate was decreased to 
200 nl/min for high resolution chromatography and introduction into the mass 
spectrometer. Analyst QS 1.0 software Service Pack 8 (ABI MDS SCIEX, Concord, 
Canada) was used to automatically attain MS data. An information-dependent 
acquisition method, consisting of a 1 s TOF MS survey scan of mass range 400–
Chapter 4                                                                Deletion of protein kinase H 
109 
 
1200 atomic mass units (amu) and two 2.5 s product ion scans of mass range 100–
1500 amu. The two most-intense peaks over 20 counts, with charge state 2–5, were 
selected for fragmentation, and a 6 amu window was used to prevent the peaks from 
the sample isotopic cluster from fragmenting again. MS/MS was put on an exclude 
list for 180 s once an ion was selected. Curtain gas was at 23 °C, nitrogen was used 
as the collision gas and ionisation tip voltage was 2700 V. 
 
4.2.8 MS data analysis 
Data were obtained and analysed from two independent experiments. ProteinPilot 
2.0.1 (Applied Biosystems/MDS Sciex) was used for the identification and 
quantification of the proteins. The Paragon algorithm integrated in the ProteinPilot 
software was used for peptide identification and was further processed by Pro Group 
algorithm for peptide identification and isoform-specific quantification, and the iTRAQ 
peak data were standardised for loading error by auto-biased corrections calculated 
using the ProteinPilot software. ProteinPilot software calculates an unused score of 2 
for a peptide with a 99 % identity confidence and an unused score of 1.3 for a peptide 
with 95 % confidence level. An unused score of >2 indicates that a minimum of two 
peptides, one peptide with >95 % confidence plus at least one other peptide with less 
than 95 % confidence, were used exclusively for the identification of that protein. With 
a protein group of highly homologous proteins (identical peptides), peptides are 
arbitrarily assigned to one protein for which an unused score and iTRAQ ratio is 
determined. The percentage of protein covered by identified sequences at a 95% 
confidence level [% Cov(95)] is calculated by dividing the number of amino acids of 
peptides identified with 95 % confidence by the total number of amino acids in the 
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protein. Relative quantification was performed on MS/MS scans and denotes the 
ratio of the areas under the peaks at 115 Da and 114 Da (untreated ΔpknH/WT), and 
117 Da and 116 Da (nitrite-treated ΔpknH/WT). 
 
4.2.9 Statistical analysis 
Statistical significance was determined with the unpaired two-tailed Student‟s test 
with GraphPad Prism Version 5. P≤0.05 was considered statistically significant. 
 
4.3 Results and Discussion 
4.3.1 The ΔpknH mutant produces low levels of PDIMs 
Previous studies have indicated that PknH may be involved in the synthesis of cell-
wall components. In our initial analysis, we characterised morphological differences 
in colony formations of all strains (Figure 4.3).  
Figure 4.3. Colony morphology. Colonies of H37Rv wild-type, ΔpknH and ΔpknH::pknH 
strains were grown on 7H10 agar plates supplemented with OADC. 10 µl aliquots from 
cultures at OD600 0.010 were inoculated to obtain colonies. Plates were sealed and incubated 
at 37 °C for 3 weeks. Scale bars = 1 mm. (Gόmez-Velasco et al., 2013). 
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We observed similar cording appearance for both the parental and complemented 
strains; however, the ΔpknH displayed a more ruffled morphology. As the cording 
appearance has been associated with virulence in M. tuberculosis the loss of PknH 
may have implications for the overall cell wall physical structure and for M. 
tuberculosis physiology.  
 
Next, we examined whether deletion of the pknH gene caused an alteration of 
specific cell-wall components by using a range of 2D-TLC solvent systems designed 
to profile a wide series of mycobacterial lipids (Dobson et al., 1985). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Apolar lipid profile of the ΔpknH mutant strain. Solvent systems SB-SD1 
were designed to visualise apolar lipids. F, free fatty acid; PAT, pentaacyl trehalose; SL, 
sulfolipid; TDM, trehalose dimycolates. TLC plates were developed by staining with 5 % (w/v) 
ethanolic phosphomolybdic acid for detecting all lipids, followed by charring at 100 °C. 
(Gόmez-Velasco et al., 2013). 
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Figure 4.5. Polar lipid profile of the ΔpknH mutant strain. Solvent systems SD2-SE were 
designed to visualise polar lipids. TLC plates were developed by staining with α-naphthol-
sulfuric acid for detecting carbohydrate containing lipids, followed by charring at 100 °C. 
DPG, diphosphotidyl-glycerol; G, glycolipid; PE, phosphatidylethanolamine; PIMs, 
phosphatidyl-myo-inositol mannosides. (Gόmez-Velasco et al., 2013). 
 
While there were no apparent differences in the cell-wall lipids between the wild type 
and the ΔpknH strain analysed using systems B-E (Figure 4.4 & 4.5) using system A, 
it was clear that the ΔpknH mutant failed to produce observable levels of PDIMs 
(Figure 4.6). In the complemented strain, ΔpknH::pknH, PDIM levels were restored 
which shows that the ΔpknH deletion mutant was able to re-establish the wild-type 
phenotype, thus ruling out the possibility of polar effects associated with knockouts of 
PDIM biosynthetic genes (Domenech and Reed, 2009). 
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Figure 4.6 Apolar lipid profile 2D-TLC of the ΔpknH mutant strain. Lipids separated 
using system A solvent system: thrice with petroleum ether (60-80 °C): EtOAc (98:2, v/v) in 
the first direction and once with petroleum ether (60-80 °C)/ acetone (98:2, v/v) in the second 
direction. TLC plates were developed by staining with 5 % (w/v) ethanolic phosphomolybdic 
acid for detecting all lipids or followed by charring at 100 °C. PDIMs were not produced in 
ΔpknH, as shown by the absence of a spot in the region marked with an ellipse.  PDIMs (I, 
phthiocerol series A; II, phthiocerol series B; III, series C in phthiodiolone family); MK, 
menaquinones; TAG, triacylglycerols. (Gόmez-Velasco et al., 2013). 
 
For further confirmation that the deletion of PknH resulted in absence of PDIMs, 
apolar lipids from each strain were analysed by labelling the cell cultures with [1-C14]-
propionate which were monitored at different time points (12 and 24 h, 5 and 10 
days) (Figure 4.7). As the growth of all the strains were similar (Papavinasasundaram 
et al., 2005), equal radioactivity was loaded on to 2D-TLCs to normalise the 
difference in PDIMs production. Thus, the spots corresponding to PDIMs (series A/B 
and C, I/II and III, in figures, respectively) from wild-type, ΔpknH and complemented 
strains were quantified by scintillation counting. Using this sensitive technique, it was 
shown that PDIMs were not entirely obliterated, but rather the observed general trend 
was the reduction in the level of PDIMs produced by the ΔpknH strain compared to 
the parental and complemented strains their levels (Figure 4.7).  
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While the profile of apolar lipids from propionate-labelled cells remained similar at 12 
and 24 h (Figure 4.7A & B), their levels were altered at 5 (Figure 4.7C &D) and 10 
days (Figure 4.7E& F). However, levels and lipid profiles of unknown lipids changed 
at 5 days (C, D) and 10 days (E, F).  Thus, radiolabelled-culture analysis, with [1-
C14]-propionate, shows there is a reduction in PDIM synthesis in the ΔpknH mutant. 
 
4.3.2 Structural analysis of total lipids from the ΔpknH strain 
Total lipids were extracted from mycobacterial strains by the Bligh–Dyer method 
(Bligh and Dyer, 1959) and were then subjected to FT-ICR MS analysis, which has 
been previously used to analyse complex lipids from M. tuberculosis (Jain et al., 
2007). The intensity of a series of molecular ions corresponding to PDIM masses 
(C86–C100) in the range of m/z range 1300–1600 were observed in the FT-ICR mass 
spectra (Figure 4.8). These PDIMs species were more abundant in the parental wild-
type strain compared to the ΔpknH mutant (Figure 4.8). There was significant 
reduction of the relative abundances of both PDIM A–B and PDIM C lipid groups in 
the mutant strain (Fig. 4.9 & 4.10). While ion species in the region between 1390 and 
1449 m/z, corresponding mainly to dimycocerosates A and B, were absent in the 
ΔpknH mutant, these peaks where more abundant in the wild-type strain, thereby 
suggesting there is a higher production of these cell components in the wild-type 
(Figure 4.8). There was partial re-establishment of the production of these same ion 
molecular species in the complemented strain (Figure 4.8). Together, results from 
this sensitive MS technique and radiolabelled-lipid experiments confirm that PDIMs 
are produced at lower levels in the ΔpknH strain compared to its parental strain. 
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4.3.3 Detection of PDIMs using immunofluorescence microscopy 
Both the mass spectrometry and TLC based techniques are unable to distinguish 
between lipids located in the cytosol and cell wall. To confirm whether the observed 
PDIM levels reflect the relative abundance of these lipids on the cell wall, synthetic 
antibodies (scFv) against PDIMS were produced and used them to monitor the 
synthesis of PDIMs using fluorescence microscopy in the mycobacterial strains. As it 
is known that M. smegmatis is unable to produce PDIMs, this bacterium was 
incubated with the antibodies and was used as a negative control in this experiment. 
In the analysis of wild-type M. tuberculosis, we observed high-intensity labelling and 
100 % co-localisation for scFv antibodies against PDIMs (Figure 4.11A). However, in 
the ΔpknH strain, a weaker fluorescence signal was detected, which corresponds to 
18 % of the relative fluorescence compared to the wild-type strain (Figure 4.11B). 
Interestingly, a stronger fluorescence signal was observed in the complemented 
strain in comparison to the parental strain, suggesting that the uncontrolled 
expression of pknH may lead to the overproduction of PDIMs. 
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A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
Figure 4.11. Immunofluorescence microscopy analysis. (A) Immunofluorescence 
microscopy analysis. Cells were labelled with rhodamine and scFv antibodies against PDIMs 
were used as primary antibodies. Anti-MBP antibody coupled to goat anti-mouse IgG-FITC 
was used as the secondary antibody. The merged images are shown in the panels on the 
right. M. smegmatis was used as a negative control. (B) Immunofluorescence detection. Data 
represent the means±SD of green fluorescence intensity (labelled PDIMs) in arbitrary units 
(a.u.), which corresponds to labelled PDIMs, per cellular area; n = 50 single bacterial cells. 
*P≤0.05. (Gόmez-Velasco et al., 2013). 
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4.3.4 Proteins involved in PDIM production are differentially regulated in the 
ΔpknH strain 
Recently, the proteome of the ΔpknH strain has been analysed and compared with 
that of the wild-type H37Rv strain. In that study, cultures grown under rolling 
conditions with or without the inducer nitric oxide in the form of 3 mM acidified nitric 
oxide were labelled with iTRAQ reagents. Using this proteomic approach, it was 
shown that the activation of the DosR regulon was subdued in the ΔpknH mutant in 
response to nitric oxide, indicating that PknH plays an important role in the control of 
the mycobacterial dormancy regulon (Chao et al., 2010). For the current study, the 
iTRAQ analysis data was examined and compared between the wild-type and the 
ΔpknH mutant strains, with particular focus on proteins involved in the biosynthesis of 
PDIMs. We detected that, without induction with nitric oxide, the levels of six out of 
the seven proteins participating in the production of PDIMs were similar when the 
mutant was compared with the wild-type strain. Interestingly, we observed higher 
levels of PpsE levels in the ΔpknH strain compared with those in the parental strain 
and these levels remained high even with induction of nitric oxide (Table 4.1). 
However, in the presence of the nitric oxide treatment, the expression of PpsD 
protein was significantly induced. Thus, the iTRAQ analysis shows that the 
expression of selected proteins of the PDIM biosynthetic pathway is affected by 
PknH and is triggered by nitric oxide.  
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Table 4.1. iTRAQ analysis of proteins encoded by the PDIM biosynthetic pathway in 
ΔpknH/pknH in presence or absence with 3 mM acidified nitric oxide. (Gόmez-Velasco 
et al., 2013). 
Protein ORF Untreated ratio Treated ratio (no. of 
peptides) 
PpsA Rv2931 1.05 0.93 (1) 
PpsD Rv2934 0.97 1.48 (1) 
PpsE Rv2935 2.36 1.93 (6) 
PapA5 Rv2939 1.16 1.16 (1) 
Mas Rv2940c 1.20 0.89 (8) 
FadD28 Rv2941 1.05 0.94 (7) 
Ketoreductase Rv2951c 1.06 1.11 (2) 
 
 
4.3.5 Lipoglycan profiles of wild type, ΔpknH and ΔpknH::pknH strains 
Results from previous in vitro and in vivo studies have provided evidence of the 
phosphorylation and interaction between PknH and EmbR (Molle et al., 2003; 
Sharma et al., 2006; Zheng et al., 2007). In M. smegmatis, overexpression of PknH 
has a positive regulatory effect on transcription of the embCAB operon via 
phosphorylation of EmbR, catalysing the arabinosylation of LM to LAM and leading to 
a higher LAM/LM ratio (Sharma et al., 2006). In view of this, we decided to extend 
our study to M. tuberculosis to characterise and quantify the lipoglycans in the ΔpknH 
strain and compare these with those of the parental and complemented strains. 
Extracted LAM and LM were purified and analysed on 15 % SDS-PAGE, as shown in 
Figure 4.9A From the 15% SDS-PAGE gel, it was shown that there were higher 
levels of LAM in the ΔpknH strain compared to the wild-type and complemented 
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strains; however, LM levels were less in the ΔpknH strain compared to wild-type and 
complemented strains. Therefore, the ratio of LAM to LM was significantly different 
between the wild-type and ΔpknH strains. For comparative analysis between each 
strain, the LAM/LM ratio was calculated using densitometric analysis (Figure 4.12B). 
The LAM/LM ratio was twofold higher in the mutant strain, whereas the 
complemented strain showed a similar LAM/LM ratio to the parental strain (Figure 
4.12B).  
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
Figure 4.12. Lipoglycan profiles of wild type, ΔpknH and ΔpknH::pknH strains. (A) 
Lipoglycans were extracted and analysed using 15% SDS-PAGE and visualised using a Pro-
Q emerald glycoprotein stain (Invitrogen) specific for carbohydrates. (B) Ratio of LAM/LM 
was calculated using densitometric analysis. 
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4.4 Conclusion 
M. tuberculosis is known to have a remarkable ability to persist within the infected 
host cell, where it can survive in a non-replicating state for several years. Despite the 
presence of an intact immune system, the tubercle bacillus can employ several 
survival strategies that can overcome cell-mediated mechanisms of immunity, thus 
allowing it to become a successful pathogen. 
 
These strategies are linked to the presence of a unique cell envelope, which contains 
many components shown to exhibit immunological activity, such as LAM (Mishra, 
Driessen, et al., 2011) and PDIMs (Rousseau et al., 2004; Astarie-Dequeker et al., 
2009; Kirksey et al., 2011). Although there is vast knowledge regarding the 
biosynthesis of cell-wall components, little is known about their regulation. An 
increased understanding of the processes involved can enhance our knowledge of 
the pathogenesis of TB. It is vital for the mycobacterial pathogen to modulate the 
production of cell-wall components during infection in response to environmental 
stimuli during infection. Recently, in vitro kinase studies have suggested that STPKs, 
present on the mycobacterial membrane, are key regulatory enzymes involved in the 
communication of such stimuli (Chao et al., 2010). However, little is known the in vivo 
interactions between STPKs and the biosynthetic enzymes of the cell wall. 
 
It has been demonstrated that infection of BALB/c mice with a pknH deletion strain 
leads to a hypervirulent phenotype, which suggested that PknH is involved in 
controlling the in vivo survival of M. tuberculosis (Papavinasasundaram et al., 2005). 
In the study, we carried out 2D-TLC analysis of cell wall lipid analyses to observe 
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whether knocking out the pknH gene affected cell wall lipid biosynthesis. The most 
significant result was that PDIMs were not produced in the ΔpknH strain, which 
suggested PknH was a positive regulator in the production of PDIMs. Through further 
experiments using more sensitive techniques including radiolabelled 2D-TLC, mass 
spectrometry and immunostaining, it was found that synthesis of PDIMs were not 
completely abolished, but their overall levels in the deletion mutant were lower 
compared to the wild-type and complemented strains. Recent studies have 
demonstrated the association of STPKs with the biosynthesis of PDIMs precursors. 
For example, PknB is involved in the phosphorylation of threonine residue(s) on 
PapA5 (Gupta et al., 2009), whereas MmpL7, a protein responsible for the transport 
of PDIMs, was identified as an endogenous substrate of PknD (Pérez et al., 2006). 
Together, these data suggest that different STPKs work together to regulate the 
biosynthesis of PDIMs.  
 
Although PDIMs were found to be produced at low levels in the mutant strain, it could 
not be disregarded that deletion of the pknH gene can potentially affect the 
biosynthesis of other cell wall components or other signalling pathways. It is well 
known that PknH induces the transcription of the embCAB operon via 
phosphorylation of EmbR (Molle et al., 2003; Zheng et al., 2007). Moreover, the over-
expression of pknH in M. smegmatis leads to a high LAM/LM ratio (Sharma et al., 
2006). Both LAM and LM behave as ligands for cell receptors on the host cell and 
play a critical role in the pathogenesis of M. tuberculosis, since they are located on its 
cell surface. Increasing evidence has led to the hypothesis that M. tuberculosis 
adapts to its human host by cloaking its cell envelope with mannosylated structures 
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which mimic the glycoforms of mammalian mannoproteins (Torrelles and 
Schlesinger, 2010). During phagocytosis, these mannosylated molecules are able to 
interact with the mannose receptor on macrophages, which contributes to the 
intracellular survival of bacilli by regulating phagosome-lysosome fusion events 
(Torrelles and Schlesinger, 2010). Therefore, the amount and nature of the mannose 
exposed on the cell surface might influence the phagocytosis event and host 
response to M. tuberculosis (Torrelles and Schlesinger, 2010). While strains with 
abundant mannose on their surface have become more host adapted, bacilli strains 
with reduced mannose are considered hypervirulent (Torrelles and Larry S 
Schlesinger, 2010). The more host-adapted strains may be highly successful in 
forming an infection and could be more likely to establish a latent infection (Torrelles 
and Schlesinger, 2010). In light of this hypothesis, an unbalanced LAM/ LM ratio 
might go some way to explaining why the ΔpknH strain became hypervirulent. In this 
study, our lipoglycan analysis revealed that the LAM/LM ratio was twofold higher in 
the ΔpknH strain compared with that in the parental strain. This result could 
potentially be due to the transcriptional effect of the embCAB operon via EmbR 
phosphorylation. Furthermore, deletion of pknH in M. tuberculosis resulted in reduced 
transcription of embB and embC in cultures treated with sublethal doses of EMB 
(Papavinasasundaram et al., 2005). 
 
The iTRAQ analysis has enabled us to get a better understanding of the signalling 
cascade that is mediated by PknH. Experimental data has revealed that seven 
proteins participating in the biosynthesis of PDIMs are differentially regulated. In 
particular, it was interesting to note that amongst all the proteins that were detected 
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in the iTRAQ experiment, the expression of PpsE protein was maintained in cultures 
in the presence and absence of nitric oxide. PpsE, a PKS, is the last enzyme 
required in synthesis of the β-diol backbone of PDIMs (Trivedi et al., 2005). In view of 
the upregulation of this enzyme, it is suggested that PpsE plays a critical role in 
PDIMs biosynthesis. In fact, studies have previously demonstrated the interaction of 
PpsE with TesA and MmpL7 (Rao and Ranganathan, 2004; Jain and Cox, 2005). 
Jain et al. has demonstrated that a domain of MmpL7 biochemically interacts with 
PpsE, which suggests that MmpL7 acts not only as a transporter but also as a 
scaffold to couple PDIM synthesis (Jain and Jeffery S Cox, 2005). PpsE can also 
form an interaction with the type II thioesterase TesA, an enzyme that might not only 
be involved in releasing the elongated phthiocerol backbone from PpsE, but also 
participate in housekeeping functions that remove inappropriate acyl units and/or 
aberrant acyl intermediates (Rao and Ranganathan, 2004). Together, these results 
indicate that PpsE may play a role as an activator or inhibitor during final PDIM 
synthesis. On the other hand, the upregulation of PpsE in ΔpknH strains treated with 
nitric oxide could be a result of the protein sensing the incorrect production of PDIMs, 
due to the lack of signalling by PknH. The replication, transcription and translation of 
a gene cluster ~50 kbp leads to the biosynthesis of PDIM, which represents a high 
energy process. Thus, it is tempting to suggest that phosphorylation, regulation by 
STPKs and protein–protein complexes may efficiently coordinate PDIM synthesis. 
 
The results from this study have shown that PknH contributes to the production and 
synthesis of M. tuberculosis cell-wall components. However, further experiments are 
necessary to understand fully how PDIM production is regulated by PknH alongside 
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other STPKs. PknH has also been established as playing an important role in TB 
pathogenesis through interaction with EmbR, a transcriptional regulator of arabinan 
metabolism in M. tuberculosis. Future efforts are needed to discover the exact role of 
the PknH-EmbR signalling system in mycobacterial pathogenesis, which eventually 
could become a therapeutic target. 
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The rapid increase in the number of cases of MDR- and XDR-TB has led to an urgent 
need for the identification of novel drug targets in M. tuberculosis and the 
development of active inhibitors against them. The unique lipid-rich cell wall of 
mycobacteria, which provides physical protection to the bacilli and can also play an 
important role in virulence, is an attractive target for the discovery of anti-TB drugs. 
Thus, improving our understanding of the structure and biosynthetic pathways of the 
mycobacterial cell wall can mediate the development of novel anti-mycobacterial 
drug targets.  
 
This Chapter summarises the findings of three different research themes covered in 
this thesis in relation to the investigation of novel targets against mycobacteria: 
identifying the cellular target of a compound with inhibitory activity against 
mycobacteria, studying the essentiality of a PPM synthase in biosynthesis of 
lipoglycans and characterising the effects of the disruption of a protein kinase in the 
synthesis of cell-wall components. 
 
 
Amongst several compounds from the ChemBridge library, AKR334 was selected for 
further studies to determine its cellular target as it displayed encouraging MIC values 
against M. tuberculosis (Ananthan et al., 2009; Maddry et al., 2009) and M. 
smegmatis. In recent times, the use of whole-cell screening has been a successful 
strategy in the identification of new anti-TB drugs including TMC207 (Andries et al., 
2005) and novel drug targets including DprE1 (Makarov et al., 2009; Christophe et 
al., 2009) and MmpL3 protein (La Rosa et al., 2012; Tahlan et al., 2012; 
Grzegorzewicz et al., 2012; Remuiñán et al., 2013). Thus, we used the same method 
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to identify the target of AKR334. From the comparative analysis of the whole-
genomic sequence of the AKR334-resistant mutant and its parental strain, it was 
found that the mutant had SNPs in the mmpL3 gene and the promoter sequence of 
the glycerol operon. Previous studies have shown that depletion of the mmpL3 gene 
leads to the accumulation of TMM molecules, thereby confirming that MmpL3 
functions as an essential membrane exporter of TMM (Varela et al., 2012). Treatment 
of M. bovis BCG with THPP and spiro analogues identified these compounds as 
inhibitors of the MmpL3 protein (Remuiñán et al., 2013). When M. smegmatis 
cultures were treated with AKR334, TMM levels remained the same in untreated and 
treated cells. This suggests that MmpL3 is not the cellular target of AKR334.  
 
The glycerol operon consists of a cluster of genes that are involved in the transport 
and metabolism of glycerol. In the AKR334-resistant mutant genomic sequence, 
single base change mutation (A to G) was detected in the promoter sequence of the 
glycerol operon. Overexpression of the genes in the glycerol operon did not cause 
resistance to AKR334 and we were unable to generate recombinant constructs 
containing the glycerol operon promoter sequence from the resistant mutant strains 
to validate the cellular target of AKR334. However, we were able to show that 
AKR334 had a greater inhibitory effect against M. smegmatis grown in glycerol-
containing media compared to M. smegmatis grown in acetate-containing media. 
Previous studies have identified PI and A039 compounds as inhibitors of the glpK 
gene in M. tuberculosis by demonstrating their ability to induce self-poisoning of M. 
tuberculosis by promoting accumulation of glycerol phosphate and ATP depletion 
(Pethe et al., 2010; Stanley et al., 2012). To discover whether AKR334 has a similar 
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mechanism of action to these inhibitors, further work by liquid chromatography/mass 
spectrometry (LC/MS) techniques can be used to examine the relative abundances 
of glycerol phosphate and ATP in various concentrations of the compound. 
Additionally, reverse transcription PCR experiments can be used to identify whether 
the expression of glycerol operon genes is altered in the AKR334-resistant mutant 
strain; this will further validate that the mode of action of AKR334 is related to 
glycerol metabolism. 
 
A PPM synthase encoded by Mt-Ppm1 (Rv2051c) has previously been shown to 
generate polyprenyl-phosphate-based mannosyl donors, such as C50/C50-P-Manp, 
that are required for the biosynthesis of higher PIMs, LM and LAM (Gurcha et al., 
2002). While this PPM synthase in M. tuberculosis is encoded by the two-domain 
gene Mt-ppm1, two neighbouring genes, in M. smegmatis it is encoded by 
MSMEG_3859 (Domain 2) and MSMEG_3860 (Domain 1) (Gurcha et al., 2002).  In 
vitro studies have previously demonstrated that Mt-ppm1/D2 and MSMEG_3859 are 
sufficient for PPM synthase activity (Gurcha et al., 2002; Baulard et al., 2003). 
However, our findings have not only demonstrated the in vivo role of MSMEG_3859 
(Domain 2, Ms-ppm1) in M. smegmatis, but they have also confirmed its essentiality 
in M. smegmatis by using CESTET, a genetic tool for testing gene essentiality. 
Additionally, using the ΔMsPpm conditional mutant, we were able to show that 
Rv3779 and PpgS, glycosyltransferases involved in AG biosynthesis, were unable to 
restore PPM synthase activity in absence of MSMEG_3859 activity; thus, discounting 
previous studies predicting their functionality as a potential secondary PPM synthase 
(Scherman et al., 2009; Skovierová et al., 2010). Together, these results indicate that 
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ppm1 is the gene encoding the sole PPM synthase in M. tuberculosis that can 
produce mannose donors for the synthesis of higher PIMs, LM and LAM and is a 
potential drug target for future anti-TB agents. 
 
M. tuberculosis possesses a distinct cell wall that is which plays a critical role in the 
interaction of the pathogen with its human host. Emerging evidence suggests that the 
synthesis of complex cell-wall complex is facilitated by serine/threonine protein 
kinases (STPKs). Using in vivo radiolabelling, MS and immunostaining analyses, we 
were able to show that deletion of one of the STPKs, PknH, leads to the attenuation 
of the synthesis of PDIMs, a major M. tuberculosis virulence lipid (Cox et al., 1999; 
Camacho et al., 2001; Rousseau et al., 2004; Astarie-Dequeker et al., 2009). We 
also found that several proteins involved in the PDIM biosynthetic pathway are 
differentially expressed in the deleted pknH strain. Furthermore, when we analysed 
the composition of the major lipoglycans, LAM and LM, and found a twofold higher 
LAM/LM ratio in the mutant strain. Thus, we provide experimental evidence that 
PknH contributes to the production and synthesis of M. tuberculosis cell-wall 
components. As PknH has previously been established as playing an important role 
in TB pathogenesis via interaction with EmbR, a transcriptional regulator of arabinan 
metabolism in M. tuberculosis, it is important that future work is conducted to 
examine the exact role of the PknH-EmbR signalling system in mycobacterial 
pathogenesis to increase our understanding of host-pathogen interactions. Together 
our results in this study demonstrated that PknH mediates the biosynthesis of cell-
wall components that possess immunomodulatory activity; thus, PknH could 
potentially be a novel target for anti-TB drugs. 
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6.1 Polymerase Chain Reaction (PCR) 
Forward and Reverse primers were designed in order to amplify the genes of 
interest. All oligonucleotides were supplied by Eurofins MWG Operon (Ebersberg, 
Germany). All reaction mixtures for the PCR using Phusion® High-Fidelity DNA 
Polymerase (New England Labs) contained the components in Table 6.1. 
 
Table 6.1 PCR reaction components. 
Component Concentration 20 µl reaction 
Milli Q water - 11.8 µl 
5X Phusion HF or GC Buffer 1× 4 µl 
10 mM dNTPs 200 µM 0.4 µl 
10 µM Forward Primer 10 pmol/µl 1 µl 
10 µM Reverse Primer 10 pmol/µl 1 µl 
Template DNA <250 ng 0.4 µl 
DMSO 100% 1 µl 
MgCl2 500 mM 0.2 µl 
Phusion DNA Polymerase 2 U/µl 0.2 µl 
 
PCR was performed in the Eppendorf mastercycler using the programme in Table 
6.2. 
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Table 6.2 Gradient PCR programme. 
Step Temperature Duration 
Initial Denaturation 98°C 30 s 
 98°C 10 s 
×35 cycles 65-80°C 30 s  
 72°C 30 s/kb            
Final Extension 72°C 10 min 
Hold 4°C ∞ 
 
Agarose gel electrophoresis was used to separate PCR products. Molecular biology 
grade agarose (Bioline) was dissolved in Tris-acetate-EDTA (TAE) buffer to produce 
0.8% or 1% agarose gels. PCR product was mixed with 6× loading dye and 
separated on the agarose gel by electrophoresis (110 – 140 V, 400mA) in TAE buffer 
alongside 1 kb DNA ladder (New England Labs). DNA was visualised by staining the 
gel with ethidium bromide for 15 mins and examined under UV light (Bio-Rad Gel 
Doc systems). DNA bands were excised with a clean scalpel and extracted from the 
gel using the QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer‟s 
instructions.  
 
6.2 DNA digestion 
Double restriction enzyme digestion reactions contained 2 µl of restriction digest 
buffer, 10 µl of purified DNA (plasmid /genomic DNA /PCR product) 1 µl of each 
restriction enzyme and 2 µl of 10× Bovine Serum Albumin (BSA) (wherever required). 
The reaction mixture was made to a final volume of 50 µl with distilled water. The 
reaction was incubated at 37 °C for 2 hours. DNA fragments were separated by 
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electrophoresis in a 1% w/v agarose gel and DNA fragments of the expected size 
were cut out of the gel and extracted as previously described in Section 6.1. 
 
6.3 DNA ligation 
Digested DNA fragments with compatible ends can be ligated using T4 DNA ligase 
(New England Labs). The ligation mixture contained 1 µl of T4 DNA ligase enzyme, 2 
µl of 10× T4 ligase buffer and required concentrations of DNA fragments. DNA 
ligation reactions were made to a final volume of 10 µl using distilled water and 
incubated at room temperature for 4 hours before leaving overnight at 4 °C. Samples 
were either stored at −20°C until further use or used instantly for transformation to E. 
coli Top10 (DH5αMCR) cells as described below in Section 6.5. 
 
6.4 Preparation of chemical competent E. coli cells 
A single colony of E. coli Top10 (DH5αMCR) was inoculated into 2.5 ml LB medium 
and incubated at 37°C overnight. The overnight culture was then used to inoculate 
250 ml LB medium with 20 mM MgSO4. Cells were grown to an OD600 0.4-0.6 and 
then harvested by centrifugation at 4500×g for 10 min at 4 °C. Cell pellets were 
gently resuspended in 1/4th volume of ice-cold TFB1 (30 mM potassium acetate, 10 
mM CaCl2, 50 mM MnCl2, 100 mM RbCl2, 15% glycerol, filter-sterilised and stored at 
4°C) and resuspended cells were incubated on ice for 5 min. Cells were harvested by 
centrifugation as described previously and were then gently resuspended in 1/25 of 
the volume of ice-cold TFB2 (10 mM MOPS or PIPES, pH 6.5, 75 mM CaCl2, 10 mM 
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RbCl2, 15% glycerol, filter-sterilised and stored at 4°C). Cells were incubated on ice 
for 15-60 min and then stored as 100 μl aliquots at -70°C. 
 
6.5 Transformation of E. coli competent cells 
E. coli competent cells were thawed on ice and mixed with 5 µl of ligation mix. Cells 
and the ligation reaction were mixed gently and then incubated on ice for 30 min. 
Cells were then transformed by heat shock at 42°C for 90 seconds followed by which 
the cells were placed on ice to cool. 500 µl of LB broth was added into the tube and 
incubated at 37°C for 1 hour with shaking. The transformed cells were then plated 
onto appropriate selection plates. 
 
6.6 Plasmid extraction 
E. coli colonies grown on selection plates were used to inoculate 5 ml of LB broth 
supplemented with appropriate antibiotic and incubated shaking at 37°C overnight. 
Cultures were harvested by centrifugation and plasmids were extracted using the 
QIAprep Spin Miniprep Kit (QIAgen) according to the manufacturer‟s instructions. All 
constructs were verified by DNA sequencing performed by Eurofins MWG Operon 
(Ebersberg, Germany). 
 
6.7 Preparation of M. smegmatis electrocompetent cells 
M. smegmatis cells were grown to OD600 0.8 and washed with 1 volume (original 
volume of culture) of 10% glycerol (filter-sterilised, pre-cooled to 4°C) twice and 
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harvested by centrifugation at 4°C at 4500g. Cells were resuspended in 1/10 volume 
of 10% glycerol and aliquoted (200 μl) for immediate use or can be stored at -70°C. 
 
6.8 Electroporation of M. smegmatis 
A 200 µl aliquot of M. smegmatis electrocompetent cells was thawed on ice and 3-5 
μl of plasmid dissolved in water was added to the cells. The mix was left on ice for 15 
minutes and then placed into a chilled 1 mm electroporation cuvette. Electroporation 
was done using an Eppendorf Electroporator (model no - 2510) at 1800V. 800 μl of 
TSB broth was added and cells were allowed to recover at 37°C for at least one 
generation time before plating on TSB agar with appropriate antibiotics. 
 
6.9 M. smegmatis genomic DNA extraction 
Cells were resuspended in 450 μl of glucose Tris-EDTA (GTE) solution (25 mM Tris-
HCl pH 8.0, 10 mM EDTA, 50 mM glucose) and 50 μl of freshly prepared lysozyme 
solution (10 mg/ml) was added. After overnight incubation at 37 °C, 500 μl of 10% 
sodium dodecyl sulfate (SDS) (Sigma-Aldrich) and 250 μl of Proteinase K (10 mg/ml) 
(Sigma-Aldrich) were added. After incubating the cells at 55 °C for 3 to 4 hours, 1 ml 
of 5 M NaCl was added and the cells were incubated at 65 °C for 15 min. Chloroform: 
isoamyl alcohol (24:1) (Fisher Scientific) extraction was performed twice to exclude 
protein. The DNA was precipitated with 2.8 ml of isopropanol (0.7 volume of total 
mixture). The samples were mixed gently by inverting the tubes, centrifuged at 3000 
rpm for 5 min and the supernatant was discarded. The DNA pellet was washed with 
10 ml of 70% ethanol and centrifuged at 3000 rpm for 5 min. After repeating the 
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ethanol wash, the supernatant was discarded and the DNA pellet was air-dried for 5 
min. The DNA pellets were dissolved in Tris-EDTA buffer containing 10 mM and 1 
mM EDTA and stored at −20 °C. 
 
6.10 Apolar and polar lipid extraction 
Polar and apolar lipids were then extracted as described previously (Dobson et al., 
1985). M. smegmatis cells were treated in 2 ml of CH3OH: 0.3 % aqueous NaCl 
(100:10, v/v) and 2 ml petroleum ether (60-80 °C) for 30 min. The suspension was 
centrifuged and the upper layer containing the apolar lipids was separated. An 
additional 2 ml of petroleum ether (60-80 °C) was added to the lower layer, mixed 
and centrifuged as described above. The two upper petroleum ether fractions were 
combined and dried under compressed N2. For polar lipids, 2.3 ml of CHCl3: CH3OH: 
0.3% aqueous NaCl (90:100:30, v/v/v) was added to the lower aqueous phase which 
was mixed for 1 h. This mixture was centrifuged and the supernatant was separated. 
The remaining residue was re-extracted twice with 750 µl of CHCl3: CH3OH: 0.3% 
aqueous NaCl (50:100:40, v/v/v). Equal amounts of CHCl3 and 0.3% NaCl (1.3 ml of 
each) were added to the pooled supernatant which was stirred for 1 h. The mixture 
was centrifuged and the lower layer containing the polar lipids was recovered, dried 
under compressed N2, and resuspended in CHCl3:CH3OH (2:1, v/v). 
 
6.11 Thin layer chromatography (TLC) analysis for lipids 
Equivalent amounts of radioactivity were spotted on TLC plates (5554 silica gel 
60F524; Merck) for further 2D-TLC analysis using following solvent systems. In case 
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of cold samples, 100 µg of apolar or polar lipids were spotted on TLC plates for 2D 
separation and analysis. Cold samples were stained with 5 % (w/v) ethanolic 
phosphomolybdic acid for detecting all lipids or α-naphthol-sulfuric acid for detecting 
carbohydrate containing lipids, followed by charring at 100 °C. Radioactive-labelled 
lipids were visualised by 48 h exposure on X-ray films by autoradiography (Kodak 
Biomax MR film). 
 
6.12 Solvent systems for 2D-TLC analysis 
Apolar lipids are separated by systems A, B, C and D. Polar lipids are separated 
using systems D and E. The solvent systems are described in Table 6.3. 
 
Table 6.3 Developing system of 2D- TLC analysis for lipid 
System Direction 1 Direction 2 
A Petroleum Ether (b.p. 60-80 °C)/ 
Ethyl Acetate 
98 : 2 (v/v) 
Petroleum Ether (b.p. 60-80 
°C)/Acetone 
92 : 8 (v/v) 
B Petroleum Ether (b.p. 60-80 
°C)/Acetone 
92 : 8 (v/v) 
Toluene/Acetone 
95 : 5 (v/v) 
C Chloroform/Methanol 
96 : 4 (v/v) 
Toluene/Acetone 
80 : 20(v/v) 
D Chloroform/ Methanol /Water 
100 : 14 : 0.8 (v/v/v) 
Chloroform/Acetone/ Methanol 
/Water 
50 : 60 : 2.5 : 3 (v/vv/v) 
E Chloroform/ Methanol /Water 
60 : 30 : 6 (v/v/v) 
Chloroform/Acetic Acid/ Methanol 
/Water 
40 : 25 : 3 : 6 (v/vv/v) 
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6.13 Dialysis of lipoglycans 
Dialysis of lipoglycans was performed using a low molecular weight cut off dialysis 
tubing, Spectra/Por membrane 6, MWCO 3,500 kDA purchased from Spectrum Labs, 
according to manufacturer‟s instructions. 
 
6.14 SDS-PAGE 
SDS-polyacrylamide gel electrophoresis technique was used for the separation of 
lipoglycans. Resolving gels of either 15% (w/v) acrylamide and a stacking gel of 12% 
were prepared and cast in the electrophoresis apparatus according to the 
manufacturer‟s instructions and run at 200 mV and 25 mA/gel until completion. 
Lipoglycans were visualised using Pro-Q Emerald Glycoprotein stain (Invitrogen) 
according to the manufacturer‟s protocol. Radiolabelled lipoglycans were visualised 
by 48 h exposure on x-ray films by autoradiography (Kodak Biomax MR film). 
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